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Abstract 
Examining The Interactive Effect Of Perceived Stigma, HIV Disclosure And Social 
Support On Long-Term HAART Adherence Among Recently-Sober HIV-Positive 
Women 
Sabine Eustache  
 
 
The discovery of highly active antiretroviral therapy (HAART) is one of the most 
remarkable scientific advances in the 30-year history of the HIV epidemic. HAART 
effectively suppresses viral load and increases CD4 count, delaying the clinical 
progression of HIV disease, reducing HIV-related morbidity and mortality and 
minimizing the risk of drug resistance.  The benefits of HAART, however, are dependent 
on strict medication adherence.  Unfortunately, many adults living with HIV do not 
adequately adhere to their medication regimen.  Estimates of average rates of non-
adherence range from 50% to 70%.  This rate is even poorer among drug users.   
Understanding the relationships between perceived stigma, HIV disclosure, and social 
support are crucial to facilitating HAART adherence, and ultimately, the clinical 
stabilization of HIV disease.  Researchers have examined the relationships between 
HAART adherence and stigma, HAART adherence and HIV disclosure and HAART 
adherence and social support, largely using cross-sectional designs. Little is known about 
the effects of perceived stigma, HIV disclosure and social support on long-term HAART 
adherence.   Even less is known about the interactive effects of these constructs. 
The purpose of this dissertation was to learn how perceived stigma, HIV 
disclosure, and social support operate together to impact long-term HAART adherence 
and HIV biological markers among women with a history of drug abuse.  This 
dissertation was a secondary analysis of Structural Ecosystemic Therapy for Adherence 
  
xiii 
(SETA), a 4-month randomized controlled intervention study designed to improve 
HAART adherence and reduce drug abuse relapse and HIV transmission risk behaviors 
among recently sober HIV-positive women.  The study analyzed quantitative data from 
171 predominately African American women. The central hypothesis of this study was 
that HIV disclosure moderates the relationships between perceived stigma and HAART 
adherence and social support and HAART adherence among HIV-positive women with a 
history of drug abuse.  
The study found HIV disclosure was unassociated with HAART adherence, viral 
load and CD4 count.  Consistent with the study’s hypotheses, higher HIV stigma 
concerns were associated with nonadherence to HAART therapy and disease severity as 
defined by viral load and CD4 count.  The study also found social support had both 
positive and negative effects on HAART adherence, viral load and CD4 count, depending 
on the domain of support.  Tests of interactions revealed significant interactions between 
the study variables.  The relationship between perceived stigma and long-term HAART 
adherence varied by disclosure.   Similarly, the relationship between perceived stigma 
and HAART adherence varied by social support and the association between disclosure 
and CD4 count varied by perceived stigma.  Adverse effects of perceived stigma 
highlights the need for continued culturally-sensitive education and training about HIV 
and AIDS.  The research findings also suggest that public health practitioners and 
medical providers should make concerted efforts to assess and address disclosure and 
stigma concerns among adults on prescribed HAART regimen.  Additionally, 
practitioners should work with adults living with HIV to understand the dynamics of the 
family and social support networks.   
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CHAPTER I:INTRODUCTION 
 1.1  Problem Statement 
The discovery of highly active antiretroviral therapy (HAART) is one of the most 
remarkable scientific advances in the 30-year history of the Human Immunodeficiency 
Virus (HIV) epidemic. HAART effectively suppresses viral load and increases CD4 
count, thereby delaying the clinical progression of HIV disease, reducing HIV-related 
morbidity and mortality and minimizing the risk of drug resistance (Garcia de Olalla et 
al., 2002; McNaghten et al., 1999; Palella et al., 1998; Paterson et al., 2000; Wood et al., 
2004).  The benefits of HAART, however, are dependent on strict medication adherence, 
closely following the prescribed treatment regimen, throughout one’s life.  Poor HAART 
adherence is associated with increased risk of adverse virologic and clinical outcomes, 
including viral replication and the development, and subsequent transmission, of 
medication-resistant HIV to sex and injection drug-sharing partners (Cain et al., 2006; 
Clavel & Hance, 2004; Cole, Hernan, Anastos, Jamieson, & Robins, 2007; Gulick et al., 
1997).  Non-adherence places the public health at undue risk, prolonging illness among 
infected individuals and increasing the risk of the spread of drug-resistant HIV disease in 
the general population. 
Most scientists agree a minimum HAART adherence rate of 95% is necessary to 
achieve effective treatment response (Paterson et al., 2000). Yet, adherence usually falls 
short of the optimal rate (Golin et al., 2002; Heckman, Catz, Heckman, Miller, & 
Kalichman, 2004; Nieuwkerk et al., 2001).  Estimates of average rates of non-adherence 
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range from 50% to 70% (M. A. Chesney, 2000).  HAART adherence is even poorer 
among drug users.  In comparative studies of HAART adherence among drug users and 
non-users, adherence rates have been found to be as much as 18% lower among drug 
users compared to nonusers (Roca, Gomez, & Arnedo, 1999). 
 Postulating individual characteristics are among the strongest predictors of 
HAART adherence, researchers have mostly used social theories of health behaviors to 
explain non-adherence to HAART therapy, primarily the Health Belief Model (Barclay et 
al., 2007; Gao, Nau, Rosenbluth, Scott, & Woodward, 2000; Malcolm, Ng, Rosen, & 
Stone, 2003) and the Theory of Planned Behavior (Powell-Cope, White, Henkelman, & 
Turner, 2003; Vissman et al., 2011).  While true, this narrow focus fails to address the 
impact of interpersonal, organizational, community and societal factors on HAART 
adherence.  Assessing HAART adherence from a social ecological framework provides 
valuable insight into the interaction and influence of broader social and environmental 
factors on HAART adherence. 
Given the number of factors that impact HAART adherence, carefully designed 
multicomponent psychosocial interventions are essential to facilitate optimal adherence 
to HIV medications.  Patient education and counseling, observed therapy, peer support 
and electronic reminder aids are among effective intervention strategies proven to 
improve HAART adherence.  For example, in a double-arm randomized controlled trial 
of HIV-positive adults, individuals who received a community based, home-visit 
intervention had improvements in adherence rates ranging from 9% to 14% higher than 
individuals in the control group at each of five follow-up visits (A. B. Williams et al., 
2006).  A growing body of literature also evidences the positive effect of social support 
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on HAART adherence (Edwards, 2006; Meade, Hansen, Kochman, & Sikkema, 2009; 
Simoni, Frick, Lockhart, & Liebovitz, 2002; van Servellen & Lombardi, 2005).  Despite 
comparable HAART adherence at baseline, average adherence at 3-month follow-up for 
individuals in a multicomponent social support intervention, for example, was 18% 
higher than members of the control group (Koenig et al., 2008).  Seeking social support, 
however, requires a willingness to disclose one’s HIV-positive status to others.  
HIV disclosure offers a number of benefits to people living with HIV and AIDS 
(PLWHA) including fewer symptoms of depression, improved access to medical care and 
HAART therapies and opportunities to explore and implement HIV risk reduction 
strategies (Armistead, Morse, Forehand, Morse, & Clark, 1999; Mills et al., 2006; Zea, 
Reisen, Poppen, Bianchi, & Echeverry, 2005).  HIV disclosure benefits also extend to the 
general population, increasing HIV awareness and HIV prevention efforts. Despite the 
advantages of HIV disclosure, many PLWHA do not reveal their status.  For many, the 
fear of HIV-related stigma and withdrawal of social support contributes to this decision 
(Clark, Lindner, Armistead, & Austin, 2003; V.J. Derlega et al., 2002; Kadushin, 1996, 
Parsons et al., 2004; Rintamaki, Davis, Skripkauskas, Bennett, & Wolf, 2006; Tufts, 
Wessell, & Kearney, 2010).  HIV disclosure has become a serious concern in the public 
health, medical, mental health, and legal communities.  Unfortunately, there are no clear 
guidelines for practitioners or PLWHA on how, when, and to whom to disclose.  
Understanding the relationships between perceived stigma, HIV disclosure, and 
social support are crucial to facilitating HAART adherence, and ultimately, the clinical 
stabilization of HIV disease.  Researchers have examined the relationships between 
HAART adherence and stigma (Rao et al., 2011; Rintamaki et al., 2006; Vanable, Carey, 
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Blair, & Littlewood, 2006; Ware, Wyatt, & Tugenberg, 2006), HAART adherence and 
HIV disclosure (Stirratt et al., 2006), and HAART adherence and social support (Catz, 
Kelly, Bogart, Benotsch, & McAuliffe, 2000; Edwards, 2006; Johnson et al., 2003; 
Meade et al., 2009; Simoni et al., 2002; van Servellen & Lombardi, 2005).  Many of 
these studies have used cross-sectional designs, assessing HAART adherence at one point 
in time. Little is known about the effects of perceived stigma, HIV disclosure and social 
support on long-term HAART adherence.   Even less is known about the interactive 
effects of these constructs. 
This dissertation examined the causal relationships between perceived stigma, 
HIV disclosure and social support, and the subsequent impact on long-term HAART 
adherence and HIV biological markers.  This research supplemented the literature by 
examining the main and interactive effects of perceived stigma, HIV disclosure, and 
social support on HAART adherence, viral load and CD4 count over time.  This 
dissertation also presented the Social Ecological Model as the conceptual framework to 
assess HAART adherence, accounting for the effects of social and environmental factors 
on medication adherence.  Understanding the interactive effects among the variables will 
help guide effective psychosocial interventions for HAART adherence. Long-term, this 
research may also assist in the establishment of guidelines for HIV disclosure for 
therapists, health care providers, and public health officials and practitioners.   
 1.2 Purpose Of Study 
The purpose of this dissertation was to learn how perceived stigma, HIV 
disclosure, and social support operate together to impact long-term HAART adherence 
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and HIV biological markers among women with a history of drug abuse.  Biological 
markers, viral load and CD4 count, reflect the severity of HIV infection and the efficacy 
of HAART.  This study consisted of a secondary data analysis of 171 participants 
enrolled in a 4-month randomized controlled intervention study that tested the efficacy of 
Structural Ecosystems Therapy (SET) (Mitrani, Szapocznik, & Robinson-Batista, 2000; 
Szapocznik et al., 2004) for improving HAART adherence and reducing drug abuse 
relapse and HIV transmission risk behaviors among recently sober HIV-positive women 
in Miami, Florida.  All women in this study met the Diagnostic and Statistical Manual of 
Mental Disorders, 4th edition (DSM-IV) requirements for abuse or dependence on an 
illegal substance within the last year but had no abuse or dependence within 60 days of 
enrollment. 
The central hypothesis of this dissertation was that HIV disclosure moderates the 
relationships between perceived stigma and HAART adherence and social support and 
HAART adherence among HIV-positive women with a history of drug abuse. Perceived 
stigma, HIV disclosure, and social support were measured using validated standardized 
instruments. HAART adherence was measured using self-report data on a standardized 
scale.  Viral load and CD4 count, biological markers for HAART adherence, were 
assessed on blood drawn from the study participants. The data obtained as part of the 
parent study has been validated and used in other published studies (Feaster, Brincks, et 
al., 2010; Feaster, Mitrani, et al., 2010). The results of this study will build on existing 
work, which examined the independent effects of perceived stigma, HIV disclosure and 
social support on HAART adherence and expand the literature to include the independent 
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and combined effects of these factors on long-term HAART adherence, viral load and 
CD4 count. 
 1.3 Specific Aims 
The specific aims and accompanying hypotheses of this dissertation were: 
Specific Aim A: To determine the independent and interactive relationships among 
perceived stigma, HIV disclosure and social support on HAART adherence.   
Hypothesis 1: Perceived stigma will be negatively related to HAART adherence. 
Hypothesis 2: Social support and HAART adherence will be positively related. 
Hypothesis 3: HIV disclosure and HAART adherence will be positively related. 
Hypothesis 4: Perceived stigma, HIV disclosure and social support will have an  
  interactive effect on HAART adherence. 
Specific Aim B:  To determine the independent and interactive relationships among 
perceived stigma, HIV disclosure and social support on viral load.   
Hypothesis 5: Perceived stigma will be positively related to viral load. 
Hypothesis 6: Social support and viral load will be negatively related. 
Hypothesis 7: HIV disclosure and viral load will be negatively related. 
Hypothesis 8: Perceived stigma, HIV disclosure and social support will have an  
  interactive effect on viral load. 
Specific Aim C:  To determine the independent and interactive relationships among 
perceived stigma, HIV disclosure and social support on CD4 count. 
Hypothesis 9: Perceived stigma will be negatively related to CD4 count. 
Hypothesis 10: Social support and CD4 count will be positively related. 
7 
 
Hypothesis 11: HIV disclosure and CD4 count will be positively related. 
Hypothesis 12: Perceived stigma, HIV disclosure and social support will have an 
 interactive effect on CD4 count. 
 1.4 Importance Of Study 
This study was the first to examine the independent and interactive effects of 
perceived stigma, HIV disclosure and social support on HAART adherence using a 
longitudinal design.  This dissertation contributed to the scientific literature by including 
the Social Ecological Model as the conceptual framework to assess HAART adherence.  
This study analyzed secondary data collected at four data points over a 12-month period. 
Perceived stigma, HIV disclosure, social support, and HAART adherence data were 
collected using validated scales while viral load and CD4 count measures were obtained 
from blood draws. The principal investigator for the parent study provided a copy of each 
database used for this dissertation. Generalized Estimating Equations (GEE) were used to 
identify predictors and uncover interactive effects on long-term HAART adherence, viral 
load and CD4 count. 
 1.5 Scope And Limitations Of Study 
Data for this secondary data analysis was obtained from a five-year study 
conducted between July 2003 and March 2007, with data collection extending through 
March 2008. The study targeted HIV-positive women age 18 years and older with a 
history of drug abuse in Miami, Florida. Ethnicity did not limit the scope of the study, 
although the vast majority of participants were African American. Study participants 
were recruited from residential and outpatient drug treatment sites, HIV treatment 
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providers, and self-referrals from word-of-mouth. A series of measurements and survey 
responses was collected for each participant at seven time points over the course of one 
year. Measurements tools were read out loud to the participant and the verbalized 
responses were recorded, thus minimizing literacy concerns.  Additionally, the tools were 
translated, and when necessary, administered in Spanish in order to avoid language 
barriers. 
Several limitations must be considered.  First, the parent study used a convenience 
sample and a relatively small sample size, which limited the generalizability of the study.  
Additionally, this study did not use a comparative sample of HIV positive women 
without a history of drug use, thus the findings could not be attributed or linked to 
substance use.  
Second, data collection was conducted five to nine years ago, raising the 
possibility that some characteristics of the population may have changed, limiting the 
generalizability of the study findings to future populations.  Although self-reported 
adherence data might be biased (H. Liu et al., 2001; Martin et al., 2009; Wagner & 
Rabkin, 2000), the use of viral load and CD4 count, biological markers for HAART 
adherence, may have helped overcome this potential limitation. 
 1.6 Definition Of Terms 
AIDS-related stigma refers to prejudice, discounting, discrediting, and 
discrimination directed at people perceived to have Acquired Immune Deficiency 
Syndrome (AIDS) or HIV and the individuals, groups, and communities with which they 
are associated (Herek et al., 1998).  
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HIV disclosure is a complex and multifaceted process of making a voluntary or 
involuntary decision about whom to inform about one’s positive HIV serostatus, why, 
when, where, and how (Eustace & Ilagan, 2010). 
Social support is a broad construct studied across multiple disciplines, which 
likely contributes to the absence of a universal definition. S. Cobb (1976) provides one of 
the earliest definitions of social support as “information leading the subject to believe that 
he is cared for and loved, esteemed, and a member of a network of mutual obligation”.  
Highly Active Antiretroviral Therapy (HAART) is the name given to a cocktail of 
three or more prescription drugs from at least two different medication classes, used to 
suppress HIV viral replication and delay the progression of HIV disease (National 
Institutes of Health, 2011). 
Medication adherence is “the extent to which a person's behavior (in terms of 
taking medications, following diets, or executing lifestyle changes) coincides with 
medical or health advice” (Haynes, Taylor, & Sackett, 1979). HAART adherence rates 
are usually reported as the percentage of the prescribed doses of the medication actually 
taken by the patient over a specified period. Some researchers, however, include dose 
taking (taking the prescribed number of pills each day) and dose timing data (taking pills 
within a prescribed period) as part of the adherence measurement (Osterberg & Blaschke, 
2005).   
CD4 count is the measurement of the number of CD4 lymphocyte cells (a type of 
infection-fighting white blood cells) in a sample of blood. The CD4 count is one of the 
most useful indicators of the health of the immune system and the progression of HIV 
disease (National Institutes of Health, 2011). 
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Viral load is the amount of HIV genetic material in a blood sample, reported as 
the number of HIV RNA copies per milliliter of blood plasma. The viral load reflects the 
number of cells infected with HIV and is an important indicator of HIV progression and 
of how well treatment is working (National Institutes of Health, 2011). 
 1.7 Dissertation Summary 
This first chapter of the dissertation provided an overview of non-adherence to 
HAART therapies and summarized the purpose of the dissertation, the research questions 
and the significance of the study.  Chapter 2 presents a review of the literature that 
provides the justification for this study, including the theoretical underpinning for non-
adherence to HAART therapy among individuals living with HIV disease. Chapter 3 
contains a detailed description of the study design, the sampling and measurement 
methods, and the data collection and data analyses procedures. Chapter 4 provides 
descriptive statistics for all of the study variables and presents the results for each of the 
study hypotheses.   The study findings are translated into the practical and conceptual 
meaning in Chapter 5.  The chapter ends with a summary of the implications of the 
findings for public health practice and future research. 
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CHAPTER II:LITERATURE REVIEW 
 2.1 History And Problem Definition 
Non-adherence to HAART is arguably the greatest public health challenge 
associated with the prevention and control of HIV disease.  Since the introduction of 
antiretroviral therapy almost 15 years ago, the benefits of HAART have been well 
documented and include delayed clinical progression of HIV disease, decreased 
incidence of opportunistic infections, fewer hospitalizations and reduced HIV-related 
deaths (Garcia de Olalla et al., 2002; McNaghten et al., 1999; Palella et al., 1998).  Near 
perfect adherence of 95% or better, however, is essential to realize the benefits of 
HAART therapy (Paterson et al., 2000).  Moreover, for sustained therapeutic benefits, 
patients must maintain near-perfect adherence, often in the absence of symptoms, for 
prolonged periods of time throughout one’s lifetime.  Non-adherence leads to a rise in 
viral load, reduction in CD4 count, development of drug-resistant HIV strains and 
increased risk for illness and even death (Cain et al., 2006; Clavel & Hance, 2004; Cole 
et al., 2007; Gulick et al., 1997).  Despite the well-documented consequences of non-
adherence, optimal HAART adherence remains a struggle for many PLWHA (Heckman 
et al., 2004; Nieuwkerk et al., 2001).  Estimates of non-adherence rates averaged from 
between 50% to 70% (M. A. Chesney, 2000).  Differences in the study population 
characteristics, study design, adherence cut-off, duration of adherence and adherence data 
collection measure may help explain the variability in the research findings.    
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Substance abusers may be particularly vulnerable to non-adherence to 
antiretroviral therapy.  While findings have been inconsistent, the majority of adherence 
research have found drug users are more likely to be non-adherent than nonusers 
(Arnsten et al., 2002; Berg et al., 2004; Fogarty et al., 2002; Gebo, Keruly, & Moore, 
2003; Golin et al., 2002; Halkitis, Palamar, & Mukherjee, 2008; C. H. Hinkin, Barclay, T. 
R., Castellon, S. A., Levine, A. J., Durvasula, R. S., Marion, S. D., et al., 2007; C. H. 
Hinkin et al., 2004; Johnson et al., 2003; Lehavot et al., 2011; Levine et al., 2005; H. Liu, 
Miller, L. G., Hays, R. D., Golin, C. E., Wu, T., Wenger, N. S., et al., 2006; Malta, 
Strathdee, Magnanini, & Bastos, 2008; Mellins, Leu, Havens, & Chesney, 2003; Sharpe, 
Lee, Nakashima, Elam-Evans, & Fleming, 2004).  In a comparative study of HAART 
adherence among drug users and non-users, adherence rates have been found to be as 
much as 18% lower among drug users compared to nonusers (Roca et al., 1999).  Only a 
few studies have found weak or no significant relationship between drug use and 
HAART (Catz et al., 2000; Crisp, Williams, Timpson, & Ross, 2004; Martini et al., 2004; 
Mohammed et al., 2004; S. A. Safren et al., 2001).  
 2.2 Magnitude And Consequences Of The Problem 
Untreated, the HIV virus replicates at a rapid rate resulting in a rise in HIV-
related illnesses, hospitalizations, and even death.  Sup-optimal treatment levels cause 
viral resistance to antiretroviral medications, and ultimately treatment failure or an 
inability to control HIV disease progression (Boden et al., 1999; Harrigan et al., 2005; 
Little et al., 1999; Wainberg & Friedland, 1998).  These drug resistant mutant strains can 
be transmitted to others (Hecht et al., 1998; Imrie, Beveridge, Genn, Vizzard, & Cooper, 
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1997; Kozal et al., 2005).  Transmission of resistant strains has serious public health 
implications, limiting treatment options for PLWHA including the newly diagnosed.  
Resistance has been linked to rapid clinical progression of disease and death (D'Aquila et 
al., 1995).   Among newly diagnosed HIV-positive individuals, the transmission rate of 
resistance-associated mutated HIV strain ranged from 5% to 16% (Boden et al., 1999; 
Wheeler et al., 2010).  
While PLWHA face a lifetime of HAART therapy, limited studies have used a 
longitudinal or prospective design investigating trends in adherence over time.  Most 
longitudinal studies have found adherence declines over time (Lima et al., 2009; H. Liu et 
al., 2006; S. Mannheimer, Friedland, Matts, Child, & Chesney, 2002; Moss et al., 2004; 
Murphy et al., 2005).  Only a few studies have found sustained and even slight increases 
in adherence over time (Cambiano et al., 2010; Carrieri et al., 2001; Halkitis et al., 2008), 
an indication that long-term HAART adherence is in fact possible.  The next section 
explores variables that both contribute to and hinder HAART adherence. 
 2.3 Key Determinants Of Non-Adherence To HAART Therapy 
 2.3.1 Theoretical Framework 
The social ecological model helps explain the interplay and influence of multiple 
social factors on HAART adherence.  The model acknowledges that although PLWHA 
are responsible for establishing and maintaining lifestyle changes necessary to improve 
health, the social environment in which a person belongs may strongly influence his or 
her behavior.  Hence, in addition to individual factors, the Social Ecological Model 
considers the effects of interpersonal, organizational, community and societal factors on 
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HAART adherence.  Figure 1 depicts the Social Ecological Model for HAART 
adherence, including the influence of perceived stigma, HIV disclosure and social 
support. 
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Figure 1: A Social Ecological Model For HAART Adherence 
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 Individual Factors Affecting HAART Adherence 
Socio-demographic factors associated with poorer HAART adherence include: 
African American race (Gifford et al., 2000; Golin et al., 2002; Halkitis et al., 2008; 
Johnson et al., 2003; Kleeberger et al., 2001; Kyser et al., 2011); younger age (Deloria-
Knoll et al., 2004; Golin et al., 2002; Gordillo, del Amo, Soriano, & Gonzalez-Lahoz, 
1999; C. H. Hinkin et al., 2004; Johnson et al., 2003; Kastrissios et al., 1998; Maggiolo et 
al., 2002); unemployment (Deloria-Knoll et al., 2004; Gordillo et al., 1999; Kyser et al., 
2011; Levine et al., 2005); low economic status (Golin et al., 2002; Kleeberger et al., 
2001); and housing instability(Kidder, Wolitski, Campsmith, & Nakamura, 2007).  A 
number of psychosocial factors have also been linked to poorer adherence including 
depression (Ammassari et al., 2004; Catz et al., 2000; Fogarty et al., 2002; Gonzalez et 
al., 2004; Gordillo et al., 1999; S. A. Safren et al., 2001), stress (Bottonari, Safren, 
McQuaid, Hsiao, & Roberts, 2010; M. A. Chesney, Morin, & Sherr, 2000; Gifford et al., 
2000; Leserman, Ironson, O'Cleirigh, Fordiani, & Balbin, 2008), avoidance-oriented 
coping (Singh et al., 1999; Weaver et al., 2005), anxiety (Campos, Guimaraes, & 
Remien, 2010; Molassiotis et al., 2002) and trauma (Mugavero et al., 2006; Whetten, 
Reif, Whetten, & Murphy-McMillan, 2008).  Characteristics of the patient’s HAART 
regimen, such as side effect severity and regimen complexity, are also associated with 
non-adherence (Battaglioli-DeNero, 2007; Catz et al., 2000; Mills et al., 2006; Roberts, 
2000; Spire et al., 2002; A. Williams & Friedland, 1997) as are positive belief about HIV 
medications and high self-efficacy (Barclay et al., 2007; Powell-Cope et al., 2003; Rudy 
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et al., 2009; Vissman et al., 2011).  Additionally, perceived stigma, discussed later in this 
chapter, is associated with non-adherence. 
 Interpersonal Factors Affecting HAART Adherence 
Researchers have found a direct association between HIV disclosure and HAART 
adherence.  There is also extensive evidence of the positive association between social 
support and HAART adherence.  Both HIV disclosure and social support are discussed at 
length later in this chapter.  Family members can be a source of stress for HIV-positive 
individuals, resulting in deterioration in adherence. Specifically, when family members 
disagree with the severity of HIV disease or are in denial about the infected person’s 
HIV, this becomes a source of stress for the infected person and has been shown to 
impede adherence (Owen, 2003). 
 Organizational Factors Affecting HAART Adherence 
A number of studies have found patients’ relationships with health care providers 
can affect HAART adherence (Bakken et al., 2000; M. Chesney, 2003; Gao et al., 2000; 
Murphy, Roberts, Martin, Marelich, & Hoffman, 2000; Schneider, Kaplan, Greenfield, 
Li, & Wilson, 2004).  The strength of the patient–provider relationship is associated with 
greater likelihood of both receiving HAART and adhering to the treatment regimen 
(Bakken et al., 2000; Beach, Keruly, & Moore, 2006; Stall et al., 1996).  Patients who 
were more engaged with their health care provider reported greater adherence to HAART 
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therapy (Bakken et al., 2000). Likewise, supportive patient-provider relationships are 
associated with better HAART adherence (van Servellen & Lombardi, 2005).  Finally, 
consistent access to health care has also been found to be associated with HAART 
adherence (Ickovics & Meisler, 1997). 
 Community Factors Affecting HAART Adherence 
The preponderance of research into community factors that affect HAART 
adherence have been conducted internationally, particularly in resource poor settings.  
Factors like transportation, access to health care, use of community health workers and 
availability of community resources (e.g. food) have been studied at length.  Community 
health workers have been shown to be an effective strategy in overcoming barriers to 
HAART adherence, particularly in resource-poor settings (Behforouz, Farmer, & 
Mukherjee, 2004; Deering et al., 2009; Mukherjee, Ivers, Leandre, Farmer, & Behforouz, 
2006).  Contrarily, poor access to transportation and medical care, and food insecurity 
have been linked to non-adherence (Au et al., 2006; Biadgilign, Deribew, Amberbir, & 
Deribe, 2009; Byakika-Tusiime et al., 2009; Deribe, Hailekiros, Biadgilign, Amberbir, & 
Beyene, 2008; Hardon et al., 2007; Marcellin et al., 2008; Nachega et al., 2006; Stout, 
Leon, & Niccolai, 2004; Tuller et al., 2010; Weiser, Fernandes, et al., 2009). While these 
studies were conducted outside of the US, researchers who have examined barriers to 
HAART adherence in developed and developing nations, have found barriers are 
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consistent across multiple settings and countries (Mills et al., 2006).  Early studies on the 
use of community health workers and food insecurity in the US support this finding.  
Kenya, Chida, Symes, and Shor-Posner (2011) reviewed 16 US-based studies that 
utilized community health workers to improve HAART and concluded the use of 
community worker is a practical and cost-effective strategy to improve HAART 
adherence.  In a cross sectional study of 104 homeless and marginally housed individuals 
in San Francisco, Weiser and colleagues (2009) found participants with severe food 
insecurity were less likely to be adherent to their HAART regimen.  Food insecurity was 
defined as “the limited or uncertain availability of nutritionally adequate, safe foods or 
the inability to acquire personally acceptable foods in socially acceptable ways”.  
Similarly, Seth C. Kalichman et al. (2011) found food insufficiency, or a lack of food, 
was related to non-adherence in an urban sample of 179 HIV-infected men and women.  
Additional research on community factors are needed, particularly in poverty-stricken 
and rural US communities with limited resources where barriers may parallel those of 
resource poor international settings. 
 Societal Factors Affecting HAART Adherence 
Few studies have explored the relationship between societal factors and HAART 
adherence.   However, as demonstrated previously, extensive research have connected 
various individual factors to adherence or non-adherence to HIV therapies. The field of 
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social psychology asserts that human behavior is influenced by interactions with other 
people and the social context within which the behavior occurs (Mcleod, 2007).  Thus, 
individual behaviors related to HAART adherence are arguably influenced by 
interactions with other people and the social context within which they occur.  For 
example, while there is no research that looks specifically at minimum wage laws and 
HAART adherence, several studies have made the connection between low 
socioeconomic status and HAART non-adherence.  Hence, one may assume laws 
affecting income, such as minimum wage laws, may in fact be related to HAART 
adherence.  Similarly, no research has examined potential correlations between 
unemployment rates and HAART non-adherence; however, a direct relationship between 
unemployment status and non-adherence is well established.  Hence, availability of jobs 
at the societal level may be related to HAART adherence.  Extensively researched 
individual-level factors can guide future studies on potential societal influencers of 
HAART adherence. 
 2.3.2 HIV Disclosure 
HIV disclosure is one of the hardest decisions facing people living with HIV and 
AIDS.  Disclosing HIV is uniquely difficult because of the virus’ association with 
homosexuality, drugs, high-risk sexual behaviors and death.  The disclosure decision is a 
complex one that not only involves deciding to reveal one’s status, but also selecting the 
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disclosure target--the person to whom the individual chooses to tell (V. J. Derlega, 
Winstead, Greene, Serovich, & Elwood, 2004).  Disclosure targets may include sexual 
partners, parents, siblings, children, extended family, friends and co-workers.   
There are both positive and negative outcomes associated with disclosing one’s 
status.  Disclosure may increase opportunities for social support, including emotional and 
instrumental support (i.e. assistance managing one’s illness, childcare, transportation) 
(Armistead et al., 1999; Black & Miles, 2002; Parsons, VanOra, Missildine, Purcell, & 
Gomez, 2004).  Individuals who disclose have fewer symptoms of depression (Armistead 
et al., 1999; Zea et al., 2005).  Additionally, disclosure to sexual or drug-sharing partners 
allows at-risk partners to play a greater role in the decision to engage or not engage in 
high-risk behaviors.  Nonetheless, even in cases of positive outcomes, the disclosure 
process is stressful for many PLWHA (S.C. Kalichman, DiMarco, Austin, Luke, & 
DiFonzo, 2003).  A valid fear resulting from HIV disclosure is stigmatization by the 
community, as well as by family and other members of one’s social network (Black & 
Miles, 2002; Bunting, 1996; V.J. Derlega et al., 2002; Vanable et al., 2006).  Additional 
negative consequences of HIV disclosure include loss of privacy (Serovich & Mosack, 
2003), rejection or abandonment (Parsons et al., 2004), discrimination (Petrak, Doyle, 
Smith, Skinner, & Hedge, 2001), relationship disruptions (Simoni et al., 1995), 
withdrawal of social support (Kadushin, 1996; Parsons et al., 2004) and violence (Gielen, 
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McDonnell, Burke, & O'Campo, 2000; Gielen, O’Campo, Faden, & Eke, 1997; 
Rothenberg & Paskey, 1995). 
PLWHA who do not disclose their HIV status are forced to take their medication 
in secret, which may hinder HAART adherence.  Rintamaki et al. (2006) found concerns 
about HIV disclosure was a statistically significant, independent predictor of HAART 
adherence.  In a qualitative study of 31 HIV positive adults, Curioso, Kepka, Cabello, 
Segura, and Kurth (2010)found fear of disclosure was a barrier to HAART adherence.  
Klitzman and colleagues (2004) found PLWHA try to hide their medication and adjust 
their dosing schedules in order to avoid being “outed”. 
 2.3.3 Perceived Stigma 
PLWHA have been stigmatized since the beginning of the epidemic 30 years ago 
(Herek & Glunt, 1988).  The virus’ association with homosexuality since the inception of 
the epidemic, and, later, drug use fosters a stigma that is more persistent than that 
associated with most any other disease (Black & Miles, 2002; Crawford, 1996).  Stigma 
can be either enacted (actual discrimination by the general public towards a person living 
with HIV) or perceived (fear or anticipation of discrimination or rejection because of 
one’s HIV-positive status) (Scambler, 1998).  For PLWHA, stigma has been linked to 
depression, anxiety, and hopelessness (Lee, Kochman, & Sikkema, 2002).  With HIV, 
there is also a pervasive environment of victim blaming (M. Cobb & De Chabert, 2002; 
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Herek, Capitanio, & Widamin, 2002; Herek & Glunt, 1988; Powell, Christensen, Abbott, 
& Katz, 1998).  Stigma has been found to be a barrier to HIV care and treatment (Brooks, 
Etzel, Hinojos, Henry, & Perez, 2005; Fortenberry et al., 2002).   
Within the HIV-related stigma literature, researchers have explored the 
relationship between perceived stigma and HIV disclosure and have found that, in 
general, the higher the level of perceived stigma, the less likely people are to disclose 
their HIV-positive status.  In a six-year study of 244 African-American women (98 HIV-
infected and 146 non-infected), Clark et al. (2003) found the more an HIV-positive 
woman perceived stigma, the less likely she was to disclose her status.  This finding did 
not change over six years.  V.J. Derlega et al. (2002) found that perceived HIV-related 
stigma predicted HIV disclosure to a parent but not to a friend or intimate partner.  
Wolitski, Pals, Kidder, Courtenay-Quirk, and Holtgrave (2009) confirmed this finding 
when comparing differences in HIV disclosure patterns among individuals with perceived 
stigma and enacted stigma.  Individuals who perceived stigma were less likely to disclose 
to their sex partners while those who experienced stigma were less likely to disclose to 
their family members, friends, and other members of their social network.   Drug users in 
this study were more likely to perceive stigma than nonusers. 
The literature has consistently documented an inverse relationship between HIV-
related stigma and HAART adherence (Rao, Kekwaletswe, Hosek, Martinez, & F., 2007; 
Rintamaki et al., 2006; Sayles, Wong, Kinsler, Martins, & Cunningham, 2009; Vanable 
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et al., 2006; Ware et al., 2006).  In a cross-sectional survey of 204 HIV-infected patients 
receiving care, Rintamaki et al. (2006) found patients with high stigma concerns were 
more than three times more likely to be non-adherent to their HAART regimen than those 
with low concerns.  Similarly, Sayles and colleagues (2009) found HIV-positive adults 
reporting a high level of internalized stigma were more likely to report poor HAART 
adherence.  These findings are consistent for infected individuals with illicit drug use 
(Knowlton et al., 2007; Ware et al., 2006). 
 2.3.4 Social Support 
With few exceptions, researchers have recognized the positive impact social 
support has on HAART adherence as well as the link between poor social support and 
sub-optimal or non-adherence to HIV medications (Burgoyne, 2005; Catz et al., 2000; 
Johnson et al., 2003).  Simoni et al. (2002) examined the association between social 
support and medication adherence in a random sample of 50 mostly African American 
and Puerto Rican men and women from an outpatient HIV clinic in New York.  The 
researchers, who assessed the influence of needed and received social support on 
HAART adherence within the last 30 days, found a significant relationship between 
social support and adherence. In contrast, participants who lacked social support were 
more likely to report of non-adherence to their HIV medications. 
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van Servellen and Lombardi (2005) conducted a cross-sectional study of 85 low-
income, Spanish-speaking, HIV-positive Latino men and women receiving treatment in 
community-based clinics in Los Angeles.  Participants reported the level of emotional or 
informational support from family and friends and their adherence to each medication in 
their regimen over four time points: yesterday, the day before yesterday, 3 days ago, and 
4 days ago.  There was a significant association between emotional or informational 
support and greater than 90% adherence during the past 4 days. 
Edwards (2006) conducted a qualitative study to examine the relationship 
between perceived social support and HAART adherence among 20 African-American 
women.  Women with supportive family members were more likely to adhere to their 
medication adherence.   Women with young children or grandchildren in the home were 
also more likely to adhere to their medications.  Additionally, women who felt supported 
and cared for by their husbands and significant others were more likely to adhere to their 
treatment regimen. Supportive family members provided both emotional and instrumental 
support.  In contrast, in the absence of perceived love, devotion, and stability from family 
and friends, women were more likely to have sub-optimal or non-adherence to their 
medications. 
In a cross sectional analysis, Vyavaharkar et al. (2007) examined the relationship 
between social support and self-reported HAART adherence among 224 HIV-positive 
women recruited from 10 community-based HIV/AIDS service organizations serving 
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rural areas.  Three dimensions of social support were measures: the availability of 
different types of support (functional support), the source of support (support network), 
and the quality of available support (satisfaction). Only 41% of women were adherent to 
their drug regimens during the past month.  Satisfaction with social support was a 
positive predictor of medication adherence. 
A number of studies have linked low or poor social support to sub-optimal or non-
adherence to HAART therapy.  Johnson et al. (2003) conducted a cross-sectional 
interview of 2,765 HIV positive adults recruited from San Francisco, Los Angeles, New 
York City, and Milwaukee.  Using self-report data, the researchers assessed HAART 
adherence over a 3-day period and level, type, and perceived satisfaction with social 
supports from one’s social network.  Almost one third of the sample (32%) was non-
adherent to their treatment regimen.  Less stable social support was associated with less 
than 90% adherence. Using data collected as part of a clinical trial on 271 HIV-positive 
adults, Meade et al. (2009) examined HAART adherence among 265 HIV-positive men 
and women with histories of childhood sexual abuse.  Participants rated their perception 
of their social support system and medication adherence in the past week. Poor social 
support was associated with poor self-reported medication adherence among the sample. 
HIV disclosure is intricately linked to the relationship between social support and 
adherence.  One must disclosure their HIV status in order to receive support, making 
disclosure a prerequisite for obtaining support.  Studies have found HIV disclosure is a 
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predictor of social support (D’Angelo et al., 2001; S.C. Kalichman et al., 2003; Zea et al., 
2005) and nondisclosure is a barrier to obtaining support (Schrimshaw & Siegel, 2003).  
Evidence from a qualitative study of 152 HIV-positive adults indicates that HIV 
disclosure can lead to support, which facilitates initiation of, and adherence to HAART 
(Klitzman et al., 2004).  In a study of 459 HIV-infected men and women initiating 
HAART therapy, Waddell and Messeri (2006) presented evidence that the positive 
association between social support and HAART adherence is contingent upon HIV 
disclosure. 
 2.4 Effective Intervention Strategies For HAART Adherence 
The arduous nature of HAART therapy and the magnitude of clinical 
consequences associated with non-adherence highlight the need for effective 
interventions.  Contrary to the 15-year history with HAART regimen, adherence 
interventions are still in their early stages (Cote & Godin, 2005).  There have only been a 
few large-scale, published intervention studies using a randomized controlled design to 
demonstrate effectiveness at promoting HAART adherence (Altice, Maru, Bruce, 
Springer, & Friedland, 2007; Koenig et al., 2008; Lucas, 2006; Milam et al., 2005; 
Remien et al., 2005; Simoni et al., 2009; A. B. Williams et al., 2006).  Arguably, the 
diversity of HIV-infected populations (i.e. MSMs, substance users, women, older adults) 
and the different considerations given to patients initiating HAART regimens and 
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patients who are non-adherent may complicate efforts to identify strategies that will 
consistently produce desired adherence rates across broad populations. 
The CDC recently identified eight interventions that have been sufficiently 
evaluated and have shown significant effects on improving HAART adherence and 
reducing viral load.  Effective strategies identified in these studies include clinic-based 
one-on-one intervention sessions with the patient’s primary care provider (Milam et al., 
2005), intervention sessions with other skilled providers (Koenig et al., 2008), home 
visits with an experienced health care professional (A. B. Williams et al., 2006); and one-
on-one and group level peer support (Simoni et al., 2009).  In addition, a couple-level 
intervention for HIV-serodiscordant couples, with an HIV-positive partner with poor 
medication adherence, has been shown to increase support and improve adherence 
(Remien et al., 2005).  Directly administered antiretroviral therapy (DAART) has been 
shown effective in suppressing viral load among active users (Altice et al., 2007) and 
users in treatment (Lucas, 2006).  More recently, researchers have examined the use of 
electronic reminder aids in promoting HAART adherence.  Preliminary findings indicate 
HAART adherence improves with electronic reminder aids (Andrade et al., 2005; Dunbar 
et al., 2003; S. A. Safren, Hendriksen, E. S., Desousa, N., Bowell, S. L., & Mayer, K. H., 
2003), although these findings are not always consistent (S. B. Mannheimer et al., 2006; 
Powell-Cope et al., 2003; Wise & Operario, 2008).  The variance in the study findings 
may be attributed to differences in study design.   
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In the randomized controlled studies of one-on-one interventions and home visits 
with skilled providers, group level peer support, programs DAART and electronic 
reminder aids, members of the intervention group consistently had better adherence than 
members in the standard of care group.  Additionally, follow-up adherence rates in the 
intervention cohort improved over baseline.  For example, despite comparable HAART 
adherence at baseline, average adherence at 3-month follow-up for individuals receiving 
Project HEART (a multicomponent social support intervention) and members of the 
control group were intervention was 46% and 28%, respectively (Koenig et al., 2008).  
Individuals who received a community based, home-visit intervention had improvements 
in adherence rates ranging from 2% (3-month follow-up) to 9% (12-month follow-up) (A. 
B. Williams et al., 2006). 
While some intervention strategies indicate promising results, the follow-up lasted 
from six to 15 months, which limits the generalizability of the findings to adherence 
beyond this time frame.  Additionally, study findings revealed the effects garnered early 
in the study were not always maintained over the study period (Koenig et al., 2008; 
Remien et al., 2005; A. B. Williams et al., 2006).  Despite extensive evidence of the 
association between social support and HAART adherence, only two interventions 
considered support as a component of their program (Remien et al., 2005; A. B. Williams 
et al., 2006).  Additionally, intervention strategies focus almost exclusively on individual 
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behaviors and do not include interpersonal, organizational, community or societal 
influences.   
 2.5 Critical Issues In Moving To The Next Stage Of Research 
Critical to moving research into long-term HAART adherence forward is the need 
to take into account a number influential constructs and potential interaction between 
constructs. As discussed in this literature review, the relationships among perceived 
stigma, HIV disclosure, social support, and HAART adherence are complex. In some 
cases circular causation may be operating; for example, HIV disclosure may lead to 
greater social support, which may lead to greater disclosure. On the other hand, it is 
possible that for some women, the circular causation may be self-damping; for example, 
current support from a social network to which the woman has not disclosed may lead to 
less disclosure, limiting new sources of social support. 
Previous research that has focused on only one or two of these potential causal 
variables leading to HAART adherence may give a somewhat distorted or incomplete 
picture of the complex psychological influences on one’s adherence behaviors, yielding 
theoretical gaps in researchers’ and practitioners’ knowledge of HAART adherence.  
Large-scale studies that gather a wide range of information on multiple variables found to 
be relevant to medication adherence, and do so over a long enough time period, are 
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crucial to reveal complex causal chains, helping to close the knowledge gap on the 
facilitators and barriers to HAART adherence. 
 2.6 Significance Of The Proposed Research 
This study was the first to examine the independent and interactive effects of 
perceived stigma, HIV disclosure, and social support on HAART adherence using a 
longitudinal design.  As such, this study helped establish critical baseline data on the 
interplay of these variables and serve as the foundation for subsequent research, 
intervention programs, and new policies.  This dissertation also contributed to the 
scientific literature by including the Social Ecological Model as the conceptual 
framework to assess HAART adherence.  Understanding facilitators of and barriers to 
HAART adherence at the individual, interpersonal, organizational, community and 
societal levels, and more specifically, the possible interplay between perceived stigma, 
HIV disclosure and social support on HAART adherence is invaluable for the design and 
development of multicomponent psychosocial intervention programs for long-term 
adherence.  Additionally, in the absence of clear guidelines for effective HIV disclosure, 
this research will assist in identifying and recommending HIV disclosure guidelines, for 
the first time, for therapists, health care providers, and public health officials and 
practitioners, and PLWHA.  
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CHAPTER III:RESEARCH METHODS 
 3.1 Context Of Research 
 3.1.1 Structural Ecosystemic Therapy For Adherence 
This dissertation was a secondary analysis of an existing intervention trial of the 
Structural Ecosystemic Therapy for Adherence (SETA) intervention.  An adaptation of 
Structural Ecosystems Therapy (Seth C. Kalichman et al.), SETA targeted interpersonal 
interactions to address HIV medical adherence, relapse prevention and HIV transmission 
risk reduction in women dually diagnosed with HIV and substance abuse. SET is a 
family-based intervention designed to improve well-being by strengthening and repairing 
relationships among family members and between the family and healthcare providers 
and family and friends (Mitrani et al., 2000; Szapocznik et al., 2004).  Like SET, SETA 
encompassed three principal techniques: joining (gaining entry into the family and 
building trust with family members); diagnosing (identifying the patterns of interactions, 
both within the family and between the family and outside systems, that prevent the 
family from being more supportive to the HIV-seropositive woman), and restructuring 
(implementing therapeutic techniques to correct maladaptive patterns of interactions) 
(Feaster, Brincks, et al., 2010; Szapocznik et al., 2004). 
During the intervention, SETA therapists conducted a clinical diagnosis of areas 
needing attention, with specific attention to HAART adherence, relapse prevention and 
33 
 
 
 
 
 
 
HIV transmission risk reduction. The therapist then developed a treatment plan 
addressing systemic problems and these three foci.  The therapist worked with the woman 
to identify family members, which included children, significant others, siblings, parents, 
extended family, health care workers and friends.  The therapist addressed the woman’s 
interactions with her family and friends and asked the women to identify family and 
friends she wanted to invite to participate in sessions with her. Family and friends were 
then recruited and were used as instruments of change to develop prosocial networks, 
prevent exposure to triggers, provide support in the event of triggers or stressors, and 
support reduction of HIV transmission risk behaviors and increased HIV medical 
adherence. 
One hundred ninety-one recently sober HIV-positive women were recruited from 
five residential and outpatient clinics in Miami-Dade County into the parent study 
between July 2003 and March 2007.  Eligible participants met the following six inclusion 
criteria:  (1) HIV-1 seropositive and meet criteria for recommending HAART (AIDS 
Treatment Information Service, 2001; Carpenter et al., 2000), (2) at least 18 years of age, 
(3) meet DSM-IV (American Psychiatric Association, 1994) requirements for abuse or 
dependence on an illegal substance within the last year, (4) have cocaine as either the 
primary or secondary drug of abuse, (5) willing to disclose HIV status to at least one 
health care professional, and (6) have at least one family member willing to participate in 
a companion study examining the family mechanisms of SETA.  Women with a DSM-IV 
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diagnosis of current abuse or dependence on an illegal substance within the last 60 days, 
a CD4 cell count less than 50, or in a phase of institutionalization in which outside 
contact was prohibited were excluded from the study.  One hundred seventy-one women 
met the inclusion criteria and were enrolled in the study.   
Participants in the (HG) met biweekly as a group with a trained interventionist at 
a community location for an average of 1.5 hours per session over a four-month period.  
Topics covered during group sessions included anatomy, sexually transmitted infections, 
HIV basics, communicating with partner, alcohol and drugs, safer sex and pregnancy, 
violence against women, and HAART adherence. Similarly, women in the SETA group 
met for 12 one-hour sessions over a 4-month period with a trained interventionist, 
although additional contact hours during three booster sessions were allowed, if deemed 
clinically necessary.  The sessions took place in the woman’s home.  
The University of Miami’s Institutional Review Board reviewed and approved the 
SETA study in June 2002, prior to data collection or contact with participants (See 
Appendix A).  Additional information about the SETA study is included in Appendix B. 
 3.2 Study Design 
This dissertation used data from a randomized intervention study testing the 
efficacy of SETA for improving medication adherence, and reducing relapse and sexual 
risk behaviors among HIV-positive women in drug recovery.  During the parent study, 
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participants completed a battery of assessments over four time periods:  at baseline, and 
at approximately 4 months, 8 months and 12 months. HAART adherence was collected at 
baseline and every other month thereafter (baseline, and at approximately 2, 4, 6, 8, 10 
and 12 months). Primary data collection occurred between July 30, 2003 and March 21, 
2008. (See Figure 2). 
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Figure 2: SETA Study Design 
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This dissertation used generalized estimating equations (GEE) with data from the 
four major data collection time points used in the parent study.  HAART adherence data 
for months 2, 6 and 10 were not included in this study.  This longitudinal design provided 
reliable insight into long-term adherence patterns and the variability of adherence 
predictors over time.  
 3.3 Study Sample 
Because intervention effects were not the focus of this dissertation, data from the 
HIV Health and SETA groups were combined for the purposes of this study.  The full 
171 women from the SETA parent study were included in the sample. All women in this 
study met the DSM-IV requirements for abuse or dependence on an illegal substance 
within the last year but had no current abuse or dependence within 60 days of enrollment.  
Intervention effect was explored and controlled for during data analysis. 
Women represent one of the fastest growing populations affected by HIV and 
AIDS.  Minority women, particularly African American women, are disproportionately 
affected with HIV across the nation, including in the state of Florida.  African American 
women are only 12% of the US population, yet account for 64% of total AIDS cases 
(Kaiser Family Foundation, 2011).  Similarly, in the State of Florida, African American 
women make up approximately 15% of the population and 69% the total statewide AIDS 
cases (Miami Dade County Health Department, 2010). 
Based on the HIV Cost and Services Utilization Study (HCSUS), the only 
nationally representative study of PLWHA receiving regular or ongoing medical care, 
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women with HIV are disproportionately uneducated, unemployed and low-income. Forty 
three percent (43%) of women had less than high school education while 30% had a high 
school education, 23% had some college education and only 4% completed college.  The 
vast majority of women (76%) were unemployed.  Nearly two-thirds of women (64%) 
had annual incomes below $10,000 and 85% had no private insurance.  More than half 
the women in the study (60%) had children; 53% of these women had more than one 
child and 76% lived with their children (Bozzette et al., 1998; Schuster et al., 2000). 
 3.3.1 Power Analyses 
Preliminary power analysis was determined using the method for longitudinal 
designs with attrition described by Hedeker and Gibbons (2006). Based on power 
analysis calculations performed with G*Power software, a minimum sample of 114 
women would provide 80% power with a medium effect size (d=0.25) to uncover a 
medium/moderate effect size (0.50SD) (Cohen, 1988).  The study sample of 171 women 
will yield a statistical power of over 80%.  Because of the multivariate model used for the 
study however, the introduction of each new variable into the GEE may have slightly 
diminished the power.  Increasing the significance level to 0.10 would have offset this 
effect. 
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 3.4 Measures And Survey Instruments 
Seven principal categories of measures were used in this dissertation: 
sociodemographic indicators, perceived stigma, HIV disclosure, social support, HAART 
adherence, viral load and CD4 cell count. During the parent study, participants completed 
a battery of assessments throughout the year.  Sociodemographic indicators were 
collected at baseline only, while data for perceived stigma, HIV disclosure, social 
support, viral load and CD4 cell count were collected over four time periods (at baseline, 
and at approximately 4 months, 8 months and 12 months). HAART adherence was 
collected at baseline and every other month thereafter (baseline, and at approximately 2, 
4, 6, 8, 10 and 12 months) (See Figure 2). Primary data collection occurred between July 
30, 2003 and March 21, 2008.  Questions were asked at each of the four or seven visits 
referred above.  Most of the data sets are organized by visit; thus a single participant was 
represented by between one and seven lines of data in the original dataset. 
 3.4.1 Sociodemographic Indicators 
Sociodemographic information was collected using a 22-item instrument used in 
previous studies conducted by the principal investigators of the SETA intervention study.  
Sociodemographic indicators included age, race and ethnicity, country of birth and 
language spoken, highest grade of education completed, employment status, receipt of 
public assistance and annual family income, sexual orientation, living situation, marital 
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and relationship status, descriptions of children, including detailed information on any 
who had died, and most recent self-reported T-cell count. 
 3.4.2 Perceived Stigma, HIV Disclosure & Social Support 
Information on the participant’s sense of stigma and her reports of persons to 
whom she had disclosed her HIV status were reported using the HIV Stigma Scale and 
Family Identification Form, respectively.  Social support was measured using 
Multidimensional Scale of Perceived Social Support, the Social Support Questionnaire  
Short Form and the FIF. 
 HIV Stigma 
Stigma was measured using the HIV Stigma Scale (HSS) (Berger, Ferrans, & 
Lashley, 2001).  The instrument measures perceived stigma associated with HIV, which 
can potentially lead to negative outcomes such as withdrawal from social activities or it 
can prevent disclosure of HIV status to friends and family.  The HSS contains 40 items 
and 4 subscales, which include personalized stigma, disclosure, negative self-image, and 
public attitudes.  Each item is responded to using a 4-point scale to indicate agreement to 
each statement.  Response choices range from strongly disagree to strongly agree. 
According to Berger et al. (2001), alpha for the scale is .96, and test-retest reliability over 
approximately 21 days is r= .92. 
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 HIV Disclosure 
HIV disclosure was captured in the Family Identification Form (FIF).  The FIF 
was used to elicit the names of all potential “family” members, including: (1) all the 
people in the participant’s home; (2) any children who did not live with her; (3) the 
primary person(s) who helped take care of her children; (4) current spouse, partner, 
boyfriend, or girlfriend; and (5) anyone not yet mentioned who the woman considered a 
major source of support. Once this list was generated, the interviewer asked a series of 
questions pertaining to each family member, depending on relationship type such as age, 
legal custodian of the child, how long she and partner had been together and if the partner 
was involved in family activities.  For each family member identified in the FIF during 
the assessment visits, the woman was asked if the individual was aware of her HIV 
status.  Individuals in the family support network who were aware of the woman’s were 
either told by the participant directly or found out independently of the participant.  The 
percentage of individuals in the family network who were aware of the participant’s HIV 
status was used in the analysis for this dissertation.  The FIF was adapted from an 
instrument utilized in a prior study with HIV-positive African American women 
(Pequegnant et al., 2001) to identify the family.  The working definition of family in the 
study included household members and others with whom the woman had regular contact 
and who had influence on the woman, especially in matters related to her health. 
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 Social Support 
The Multidimensional Scale of Perceived Social Support (MSPSS) measures 
perceived support but focuses on the degree of satisfaction with perceived social support 
from family, friends, and a significant other (Dahlem, Zimet, & Walker, 1991; Zimet, 
Dahlem, Zimet, & Farley, 1988).  The 12-item scale yields three subscores for family, 
friends and significant other and the mean overall support score.  Response choices range 
on a 7-point scale from very strongly disagree to very strongly agree. In the present 
study, scores were reported as average response across items, thus ranging from 1.0 to 
7.0.  Higher scores indicate higher levels of perceived social support.  Canty-Mitchell and 
Zimet (2000) reported a Cronbach’s alpha of .93 and Zimet et al. (1988) reported test-
retest reliability of .85 over 2-3 months. The scale has frequently been used for patients 
living with HIV/AIDS.  Only mean overall support scores were used in this study. 
The Social Support Questionnaire (SSQ) Short Form (Sarason, Sarason, Shearin, 
& Pierce, 1987) was also used to measure perceived social support.  The 6-item 
instrument yields two scores:  the Perceived Availability Score (SSQ-Availability) and 
the Satisfaction Score (SSQ-Satisfaction).  The SSQ-Availability measures the average 
number of network individuals available and the SSQ-Satisfaction measures the 
respondent’s satisfaction with available support.  Response choices range from strongly 
disagree (1) to strongly agree (6) on a Likert scale.  On both scales, higher scores indicate 
greater levels of social support.  According to the authors, coefficient alphas ranged from 
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.90 to .93, showing a high level of internal consistency, and test-retest correlations of .84 
for Availability and .85 for Satisfaction over a period of 3-4 weeks. The scores for each 
of the six aspects of support as well as the overall scores for SSQ-Availability and SSQ-
Satisfaction were used in the analysis for this dissertation.   
The Size of the Support Network was obtained from the FIF.  Participants were 
asked to generate a list of individuals in their family or support network.   The number of 
individuals in the family network was included as a social support measure and was used 
in the analysis for this dissertation.   
 3.4.3 HAART Adherence, Viral Load, and CD4 Count 
 HAART Adherence 
Self-report adherence to HIV drug therapy was measured over a 4-day period 
using the AIDS Clinical Trials Group (ACTG) Adherence Interview Questionnaire (M. 
A. Chesney, Ickovics, et al., 2000).  At each of up to seven visits, for each of up to five 
drugs, participants were asked to identify (1) the number of times they were supposed to 
take a certain medication on a given day, (2) the number of pills they were supposed to 
take each time they took the medication, and (3) the number of pills they missed in each 
of the prior four days.  Many questions also addressed reasons for skipping doses, 
including questions on symptoms that might be associated with side effects.  Percent 
adherence was calculated for the past four days and for each day within that time frame.  
44 
 
 
 
 
 
 
Percent adherence was calculated based on number of medications taken divided by 
number of medications prescribed.  Participants’ responses were dichotomized as 
adherent or taking at least 90% of the prescribed dose (value=1) and non-adherent, taking 
less than 90% of prescribed doses (value=2) as a compromise between the 95% 
adherence recommended by the World Health Organization (WHO) and more recent 
recommendations of 80–90% adherence for acceptable suppression of viral replication 
(Bangsberg, 2006; Parienti et al., 2008).  
 Viral Load 
Viral load was assessed on blood draws obtained at baseline and approximately 
months 4, 8, and 12 of the study period.  Viral Load Blood HIV-1 RNA levels were 
obtained using reverse transcriptase polymerase chain reaction (RT-PCR) by Roche with 
a detection range of 400–750,000 copies/ml.   
 CD4 Count 
CD4 count was assessed on blood draws obtained at baseline and approximately 
months 4, 8, and 12 of the study period.  T-cell Subset (CD4/CD8) lymphocyte 
phenotypes were obtained using BD Biosciences FACSalibur 4-color flow cytometer and 
monoclonal antibodies for lymphocytes, T cells, T-helper and suppressor cells.   
 The psychometric properties of each scale are summarized in Table 1.   
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Table 1:  Psychometric Properties of the Principal Measurement Scales 
 
Psychometric	  Properties	  of	  the	  Principal	  Measurement	  Scales	  
Scale	   No.	  of	  Items	  
Theoretical	  
Range	  
Mean	   SD	  
Actual	  
Range	  
AIDS	  Clinical	  Trials	  
Group	  (ACTG)	  Adherence	  
Interview	  Questionnaire	  
44	  main	  
questions;	  
hundreds	  of	  
optional	  
responses	  
0.00-­‐1.00	   .817a	   0.389	  
0.00-­‐
1.00	  
Social	  Support	  
Questionnaire	  (SSQ)	  
Short	  Form	  
6	   1-­‐36	   6.80	   3.80	   1-­‐21	  
Multidimensional	  Scale	  
of	  Perceived	  Social	  
Support	  (MSPSS)	  	  
12	   1.0-­‐7.0	   5.43	   1.10	   1.0-­‐7.0	  
HIV	  Stigma	  Scale	  (HSS)	   40	   40-­‐160	   91.0	   23.9	   40-­‐156	  
 
 3.4.4 Minimizing Measurement Bias 
Self-report of HAART adherence is subject to measurement bias including recall 
bias, response bias and social desirability.  There are inconsistent reports about the 
accuracy of self-reported HAART adherence in the literature (Garber, Nau, Erickson, 
Aikens, & Lawrence, 2004).  Self-report data can limits the credibility and validity of the 
study findings.  Given the positive association between HAART adherence and biological 
markers (viral load and CD4 count) (Le Moing et al., 2001), self-report HAART 
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adherence data, viral load and CD4 count were included as outcome measures for this 
dissertation.   
 3.4.5 Training And Supervision Of Data Collectors 
During the parent study, data personnel received thorough training and close 
supervision, ensuring accurate data collection and good-quality data for this secondary 
analysis.  The two-day training focused on teaching data collectors the purpose of each 
data collection instrument, the intrinsic value of good-quality data and how to ensure data 
quality during data collection and entry. Additionally, given the sensitive nature of the 
data collected, research staff took care to recruit interviewers who were culturally-
sensitive and able to establish trust and develop rapport with the study participants.  This 
included inclusion of bilingual Spanish/English staff as part of the research team. 
In order to avoid barriers due to literacy during data collection, trained data 
collectors supplied a copy of the instrument for the respondent to hold, read each of the 
items and responses to the respondent and documented the verbalized response, which 
were later entered into the research database.  The data collection instruments were 
available, and administered, in Spanish when appropriate.  Data collection staff and the 
study investigators met regularly as a team to identify and rectify any problems with data 
collection.  Additionally, the study was monitored every six months by a departmental 
quality assurance unit administered independently of the research study. Monitoring was 
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designed to prevent drift in procedures, ensure full human subjects and regulatory 
compliance, and verify completion and accuracy of case report forms. Quality reports 
were made to the principal investigator and local Institutional Review Board (IRB).  
 3.5 Data Storage and Security 
The principal investigator (PI) for the parent study supplied SPSS files with the 
electronic data for this dissertation project.  Only the data for those variables included in 
this study were provided.  The dataset was completely de-identified.  Additionally, the 
linking list which links the study participant to the assigned unique identifier had been 
destroyed, making the identification of the study participants impossible. 
The study data was stored on a password-protected personal computer, which 
locked after a couple of minutes of inactivity, housed in the PI’s office.  Only the PI had 
the password for this computer.  Immediately following completion of this dissertation, 
all of the data for this study, including the datsets and analyses, were archived to a CD-
ROM, which will be kept in a locked cabinet for five years, then destroyed.   The data 
was deleted from the PI's personal computer following archive to the CD.  These 
measures made the risk of loss, unauthorized access, or divulgence of confidential 
information highly improbable. 
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 3.6 Data Analysis Plan 
Data was entered into SPSS 19.0 for Mac.  Preliminary data analyses were 
conducted to identify outliers, correct the data for skewness and kurtosis by means 
customarily used by researchers in the field, and assess the assumptions of the statistical 
analyses.  Descriptive statistics were reported on the sample demographics and the 
research variable composite scores to provide a description of the data.  Univariate 
analyses were used to examine relationships between the independent and outcome 
variables.  Multivariate analyses, using GEE, were then used to assess the main and 
interactive effects of perceived stigma, HIV disclosure and social support on HAART 
adherence, viral load and CD4 count.   
 3.6.1 Testable Model 
Figure 3 depicts the testable model for the three outcome variables.   The analysis 
plan for study’s hypothesis follows.  
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Figure 3: Testable Model
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 3.6.2 HAART Adherence 
 The hypotheses relative to HAART adherence were: 
Hypothesis 1: Perceived stigma will be negatively related to HAART adherence. 
Hypothesis 2: Social support and HAART adherence will be positively related. 
Hypothesis 3: HIV disclosure and HAART adherence will be positively related. 
Hypothesis 4: Perceived stigma, HIV disclosure and social support will have an  
  interactive effect on HAART adherence. 
Data analysis for HAART adherence was conducted in three major steps.  The 
first step was univariate analyses with the use of baseline data.  Generalized estimating 
equations (GEE) were used to evaluate the independent impact of sociodemographic 
factors, perceived stigma, HIV disclosure, and social support measures on HAART 
adherence.  This step was conducted to establish independent associations of the main 
effect of sociodemographic factors, perceived stigma, HIV disclosure and social support 
on the HAART adherence at baseline.  Logistic regression models were used to examine 
these steps.   For the second step, univariate analyses were repeated except repeated 
measures of the independent and outcome variables were used.  Odds ratios (OR) and 
associated p-values were obtained.  Given the modest sample size, borderline 
significance levels up to 0.10 were considered a significant finding. 
The final step of the analyses was the multivariate analysis.  One GEE models 
was fitted for HAART adherence in order to test the study’s hypotheses.  Using a forward 
selection procedure, perceived stigma, HIV disclosure, social support study variables and 
the possible explanatory sociodemographic variables were added one by one into the 
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regression models for HAART Adherence, viral load and CD4 count.  Randomization 
assignment (whether the client ID was randomized into the SETA intervention group or 
the HG control group) and time elapsed (the number of days from baseline) were 
introduced into the model first to control for intervention effect and account for temporal 
change.  These variables remained in the model regardless of their significance level.  
The study variables were then introduced individually, starting with the variable with the 
most significant level or the variable with the lowest p value from the univariate analyses.  
All of the constructs of perceived stigma, HIV disclosure and social support were entered 
into the multivariate models.  Most of the sociodemographic factors were also introduced 
into the models as covariates.  Marital status, sexual orientation, language and country of 
birth were not included in the model as the scientific literature does not support a 
significant relationship between these variables and HAART adherence.  Data from all 
four data collection points over the 12-month study period were used for the analyses.  
Following the fit of independent variables, interactions of interest between perceived 
stigma, HIV disclosure and social support were introduced into the model and fitted for 
significance.  Odds ratios (OR), 95% confidence interval (CI) and associated p-values 
were obtained for each predictor in the models.  A significance level of 0.10 was used to 
account for the small sample size.   
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 3.6.3 Viral Load 
The hypotheses relative to viral load were: 
Hypothesis 5: Perceived stigma will be positively related to viral load. 
Hypothesis 6: Social support and viral load will be negatively related. 
Hypothesis 7: HIV disclosure and viral load will be negatively related. 
Hypothesis 8: Perceived stigma, HIV disclosure and social support will have an  
  interactive effect on viral load. 
Data analyses for hypotheses 5-8 were similar to that used for HAART adherence.  
The sample three steps of analyses were conducted.  However, simple linear models were 
used instead of logistic regression.  Beta values (β), 95% CI and associated p-values were 
obtained and used to interpret the findings.  A significance level of 0.10 was used to 
account for the modest sample size. 
 3.6.4 CD4 Count 
The hypotheses relative to CD4 count were: 
Hypothesis 9: Perceived stigma will be negatively related to CD4 count. 
Hypothesis 10: Social support and CD4 count will be positively related. 
Hypothesis 11: HIV disclosure and CD4 count will be positively related. 
Hypothesis 12: Perceived stigma, HIV disclosure and social support will have an  
  interactive effect on CD4 count. 
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Data analyses for hypotheses 9-12 were identical to that conducted for viral load. 
 3.7 Ethical Considerations 
This study was submitted for exemption review with Drexel University’s IRB, as 
the research involved unique identifiers and coded data and study participants could not 
be identified, directly or through the available data.  All enrolled participants provided 
informed written consent prior to participating in the intervention study, which addressed 
use of the study data for secondary analysis.  Sources of the existing data and information 
from the original approved University of Miami IRB application were included as part of 
the IRB application.  An official letter from the PI of the parent study authorizing use of 
the data set also accompanied the IRB application.  The IRB application was approved on 
February 15, 2012. 
There were minimal risks to participants relative to the secondary data analysis 
conducted during this dissertation, as participant-identifiable data was not provided in the 
study database.  Study participants were not identifiable in any way to the researcher and 
were not identifiable in the final report. 
 3.8 Potential Barriers To Conducting Research 
As a secondary analysis of data already obtained, barriers to research that might 
be problematic in other studies were absent for this dissertation. However, the data itself 
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presented some notable hurdles. Specifically, the information available was enormous. 
The original data for this study was contained in seven separate datasets, some of which 
were very large.  For example, the SSQ dataset used in the study included 525 reports on 
members in the participants’ support network and 437 variables, for a total of 229,425 
cells. A great deal of time was required simply to determine which of the many variables 
in the datasets were relevant to the proposed study.  Additionally, in some cases, the 
analytic variable for the study had to be created. 
Although the data was complex, one of the principal propositions of this 
dissertation was that previous studies have often neglected to take into account the 
complexity of the relationships among factors that influence HAART adherence. Thus, a 
full exploration of these complex variables required a complex data set. 
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CHAPTER IV:RESULTS 
This chapter will review the statistical findings of this study, divided in several 
sections: first an overview of the study population and the research variables will be 
presented through the descriptive statistics.   The results of the univariate analyses will 
follow in order to understand the independent relationships between perceived stigma, 
HIV disclosure and social support and the study outcomes (HAART adherence, viral load 
and CD4 count).  The chapter will conclude with the results of the GEEs which were 
used to explore the study’s hypotheses. 
 4.1 Description Of Sample 
 4.1.1 Sample Size 
The study included data collected for 171 women at four time points (baseline and 
months 4, 8 and 12) during a year-long period.  While the parent study collected self-
reported adherence data at three additional time points (months 2,6 and 10), those data 
were not included in this analysis. Thus, each respondent could have a maximum of four 
data collection time points in this secondary data analysis study.  Actual number of visits 
per respondents ranged from 1-4.  In total, the 171 women generated 499 repeated 
measures of responses.  
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 4.1.2 Sociodemographic Characteristics 
Table 2 contains a summary of the sample demographics.  All women in the study 
had at least one lifetime DSM–IV substance use diagnosis but had not abused or 
depended on an illegal drug at least 2 months prior to enrollment.  The participants 
ranged in age from 22 to 63 years old at the time of enrollment.  The mean age of 
participants at the time of enrollment into the study was 42.5 years old (SD= 7.2). The 
vast majority of participants were non-Hispanic Black (81.6%) while 12.3% were 
Hispanic, 5.5% were White, and 0.6% identified as American Indian or Alaska Native.  
Most participants (88.4%) were born in the United States, and for 93.9% of the sample, 
the preferred language was English.  Approximately one half of the participants reported 
less than a high school education (50.6%) and 28% reported having a high school degree 
or equivalent.  Some participants (19.5%) reported technical school training or some 
college.  Few reported having a college degree or some graduate school training (1.8%).    
The mean total annual family income (estimated from last Internal Revenue Service 
report) was $6,843The median income reported was $6,950, and income at the 75th 
percentile was $9,910.  Almost one third of participants (30.2%) reported zero income.  
Only 9.4% had an income of greater than $15,000.  Of the sample, 89.6% were 
unemployed and 77.9% were on public assistance.  Eighty seven percent of women were 
heterosexual and 12.8% were either gay or bisexual.  Marital status was reported as: 
40.5% single, 9.2% married and living with spouse, 25.1% separated or divorced, 8.0% 
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widowed, and 17.2% living with a partner.  Most women (87.1%) had at least one child.  
Year with HIV diagnosis ranged from 1982 to 2007, with a mean self-reported number of 
years since diagnosis of 10.5 years.     
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Table 2:  Sociodemographic Characteristics Of The Study Population 
 
Sociodemographic	  Characteristics	  of	  the	  Study	  Population	  (n=171)	  
Characteristics	   Frequency	   Percent	  
Race/Ethnicity	   	   	  
Black	  or	  African	  American	   133	   81.6%	  
Spanish	  origin,	  Hispanic	  or	  Latino	   20	   12.3%	  
White	   9	   5.5%	  
American	  Indian	  or	  Alaska	  Native	   1	   <1%	  
Country	  of	  Origin	   	   	  
Born	  in	  the	  US	   145	   88.4%	  
Born	  outside	  of	  the	  US	   19	   11.6%	  
Preferred	  Language	   	   	  
English	   154	   93.9%	  
Spanish	   9	   5.5%	  
Both	  English	  and	  Spanish	   1	   <1%	  
Sexual	  Orientation	   	   	  
Heterosexual	   143	   87.2%	  
Gay	   5	   3.0%	  
Bisexual	   16	   9.8%	  
Marital	  Status	   	   	  
Never	  married	  and	  not	  living	  with	  a	  partner	   66	   40.5%	  
Married	  and	  living	  together	   15	   9.2%	  
Married	  but	  living	  apart	   16	   9.8%	  
Living	  with	  partner	   28	   17.2%	  
Widowed	   13	   8.0%	  
Divorced	   25	   15.3%	  
Educational	  Attainment	   	   	  
No	  formal	  training	   2	   1.2%	  
Less	  than	  high	  school	  diploma	   81	   49.4%	  
High	  school	  diploma	  or	  GED	   46	   28.0%	  
Completed	  technical	  school	   8	   4.9%	  
Some	  college	  or	  2	  year	  degree	   24	   14.6%	  
Four	  year	  degree	   2	   1.2%	  
Post-­‐graduate	   1	   <1%	  
Employment	  status	   	   	  
Unemployed	   147	   89.6%	  
Employed	   17	   10.4%	  
Receives	  public	  assistance	   127	   77.9%	  
Has	  children	   142	   87.1%	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 4.2 Exploration Of Data And Creation Of Analytic Variables 
 4.2.1 Sociodemographic Factors 
Sociodemographic variables were explored for outliers, skewness and normality.  
Four variables were re-categorized to correct for non-normal distribution and small 
samples within specific categories.  Education was categorized as “less than high school 
education”, “high school diploma or GED” and “more than high school education”.  
Race/Ethnicity were dichotomized into “African American” and “Other”.  Language and 
sexual orientation was also dichotomized into “English” and “Other” and “Heterosexual” 
and “Other”, respectively.  The recoded values were used in the univariate and 
multivariate analyses. 
 4.2.2 Perceived Stigma 
At 92.45 score, mean overall stigma fell within the lower end of the 40-160 
possible score at baseline.  The mean personalized stigma score for this time was 40.34 
and the scores for disclosure concerns, negative self image and concerns about public 
attitude subscales were 24.92 (range =10-40), 27.54  (range=13-52) and 46.52 (range 20-
80), respectively.   Subscale scores and the overall score changed minimally as time 
progressed during the 12-month period (See Table 3).  Only the aggregate stigma scale 
score was included in the univariate and multivariate analyses.   
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Table 3:  Descriptive Statistics: Perceived Stigma 
 
 
 
	   	  
Baseline	  
4-­‐month	  
follow-­‐
up	  
8-­‐month	  
follow-­‐
up	  
12-­‐
month	  
follow-­‐up	  
Personalized	  Stigma	   Mean	   40.34	   38.82	   38.51	   40.67	  
Median	   11.835	   12.316	   12.541	   13.926	  
Minimum	   0.149	   -­‐0.047	   0.234	   0.251	  
Maximun	   -­‐0.334	   -­‐0.710	   -­‐0.178	   -­‐0.481	  
Disclosure	  concerns	   Mean	   24.92	   24.08	   23.51	   24.79	  
Median	   6.149	   6.346	   6.566	   6.617	  
Minimum	   0.036	   -­‐0.102	   -­‐0.025	   -­‐0.155	  
Maximun	   -­‐0.092	   -­‐0.391	   -­‐0.325	   -­‐0.356	  
Negative	  Self-­‐Image	   Mean	   27.54	   27.10	   27.22	   28.38	  
Median	   8.229	   8.114	   7.830	   8.857	  
Minimum	   0.388	   0.367	   0.387	   0.311	  
Maximun	   -­‐0.276	   -­‐0.495	   0.048	   -­‐0.449	  
Concerns	  about	  Public	  
Attitude	  
Mean	   46.52	   44.83	   44.15	   46.50	  
Median	   12.631	   12.859	   13.826	   14.500	  
Minimum	   0.092	   0.006	   0.228	   0.120	  
Maximun	   -­‐0.180	   -­‐0.365	   0.040	   -­‐0.453	  
Overall	  Stigma	  Score	   Mean	   92.45	   88.86	   88.43	   92.64	  
Median	   22.819	   23.742	   24.429	   26.378	  
Minimum	   0.164	   0.100	   0.179	   0.150	  
Maximun	   -­‐0.149	   -­‐0.313	   0.126	   -­‐0.397	  
 
  
 4.2.3 HIV Disclosure 
A summary of the disclosure data is provided in Table 4.  The proportion of the 
network aware of the woman’s HIV status ranged 0% to 100%.  The baseline mean was 
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78% and this proportion increased slightly during the 12-month period:  80% at the 4-
month, 80% at the 8-month and 83% at 12-month follow-up visits.    
 
Table 4:  Descriptive Statistics: HIV Disclosure 
	  
	   	  
Baseline	  
4-­‐month	  
followup	  
8-­‐month	  
followup	  
12-­‐
month	  
follow-­‐up	  
Disclosure	  Proportion	   Mean	   0.7836	   0.8048	   0.801	   0.829	  
Median	   0.29012	   0.27445	   0.270	   0.234	  
Minimum	   -­‐1.176	   -­‐1.374	   -­‐1.322	   -­‐1.364	  
Maximum	   0.239	   1.011	   0.953	   1.443	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 4.2.4 Social Support 
With the exception of the availability of, satisfaction with and size of support 
variables, the analytic variables for the social support variables were calculated in the 
original dataset.  Availability of social support and satisfaction with social support scores 
were calculated prior to running the descriptive statistics.  The availability score was 
obtained by calculating the mean for the availability scores provided in the original 
dataset.  The satisfaction score was obtained by dividing the sum of the score for all items 
by 6, the number of items.  This yielded availability scores and satisfaction scores that 
ranged between 0 and 8.67 and 1 and 6, respectively.  The size of the support network 
was calculated with data provided in the FIF.  A count of the initials reported for the 
members of the woman’s support network at each of the data collection time point made 
up the analytic variable.  Information for all of the support variables is detailed in Table 
5. 
With the exception of the Size of Support Network, mean values for the social 
support variables remained relatively constant.  The mean network size, however, 
increased as time progressed.  While descriptive for subscale scores are presented in 
Table 4.4, only overall scores were included in the univariate and multivariate analyses. 
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Table 5:  Descriptive Statistics: Social Support 
	  
	   	  
Baseline	  
4-­‐month	  
follow-­‐
up	  
8-­‐month	  
follow-­‐
up	  
12-­‐
month	  
follow-­‐up	  
Mean	  Family	  Support	   Mean	   5.5894	   5.6108	   5.5814	   5.491	  
Median	   1.29237	   1.38644	   1.26981	   1.459	  
Minimum	   -­‐1.214	   -­‐1.340	   -­‐0.625	   -­‐0.937	  
Maximum	   1.984	   2.107	   -­‐0.229	   0.558	  
Mean	  Friend	  Support	   Mean	   4.9892	   5.0843	   5.000	   4.788	  
Median	   1.50844	   1.42032	   1.504	   1.535	  
Minimum	   -­‐0.828	   -­‐0.611	   -­‐0.663	   -­‐0.816	  
Maximum	   0.372	   0.348	   0.263	   0.244	  
Mean	  Significant	  Other	  
Support	  
Mean	   6.0467	   6.0426	   6.003	   6.011	  
Median	   1.028	   1.140	   1.072	   1.221	  
Minimum	   -­‐1.810	   -­‐1.855	   -­‐1.518	   -­‐1.614	  
Maximum	   5.770	   4.717	   4.247	   3.163	  
Mean	  Overall	  Support	   Mean	   5.542	   5.579	   5.528	   5.430	  
Median	   1.055	   1.116	   1.059	   1.150	  
Minimum	   -­‐1.182	   -­‐1.302	   -­‐0.957	   -­‐1.073	  
Maximum	   2.952	   3.235	   2.217	   1.867	  
Availability	  of	  Social	  
Support	  
Mean	   1.676	   1.697	   1.605	   1.555	  
Median	   1.257	   1.473	   1.178	   1.191	  
Minimum	   1.353	   1.549	   1.038	   1.408	  
Maximum	   1.934	   3.931	   1.047	   2.677	  
Satisfaction	  with	  Social	  
Support	  
Mean	   5.776	   5.693	   5.764	   5.502	  
Median	   0.681	   0.905	   0.688	   1.216	  
Minimum	   -­‐5.023	   -­‐3.867	   -­‐4.733	   -­‐3.060	  
Maximum	   27.919	   15.247	   27.105	   8.630	  
Size	  of	  Support	  Network	   Mean	   4.450	   5.060	   5.18	   5.22	  
Median	   2.650	   2.720	   2.843	   2.612	  
Minimum	   1.067	   0.891	   1.002	   0.932	  
Maximum	   1.460	   0.972	   1.684	   1.613	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 4.2.5 HAART Adherence 
The analytic variable for HAART adherence was recoded for this secondary data 
study.  The original adherence variable reflected self-report of at least 90% adherence for 
women on a prescribed HAART therapy.  All women enrolled in the study, however, 
were medically eligible for HAART therapy. HAART adherence was recoded so that 
women not on HAART were classified as non-adherent.   The distribution of the recoded 
adherence variable is depicted in Figure 4.   
There was a slight increase in the number of respondents who reported being 
adherent to their HAART regimen at the 4- and 8-month follow up visits.  Responses 
remained the same between the 8- and 12-month follow up visits, although the number of 
women on a prescribed regimen increased over time.   
    65 
  
 
 
 
 
 
Figure 4: Distribution Of HAART Adherence By Time
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8-month 
followup 
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followup 
Nonadherent 42% 38% 31% 31% 
Adherent 59% 62% 69% 69% 
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 4.2.6 Viral Load 
Based on the asymmetry, and non-normal distribution of viral load, a log (base 
10) transformation was applied to viral load data and the log-transformed variable was 
used as the outcome variable for this study.  The log-transformed variable exhibited 
improved symmetry and near normal distribution (See Table 6).  Mean viral load 
remained relatively stable throughout the study period.  Mean values for the transformed 
variables were 2.93 at baseline and 2.79, 3.12 and 2.78 at 4-, 8- and 12-month follow up, 
respectively.   
 4.2.7 CD4 Count 
CD4 count data was considerably asymmetrical and non-normal.  A log-
transformation was completed to approximate a normal distribution.   The mean values 
for the transformed data were 2.56 at baseline, 2.61 at 4-month follow up, 2.55 at 8-
month follow up and 2.60 at 12-month follow up  (See Table 6).  While the 
transformation improved the distribution, the data remained non-normally distributed.  
The log-transformed variable was used in further analyses, as this is the analytic variable 
used in published studies of CD4 count. 
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Table 6: Descriptive Statistics For Viral Load And CD4 Count 
	   	  
Baseline	  
4-­‐month	  
followup	  
8-­‐month	  
followup	  
12-­‐month	  
followup	  
Log	  Viral	  Load	   Mean	   2.929	   2.786	   3.117	   2.783	  
Median	   2.806	   2.481	   3.041	   2.592	  
Minimum	   1.400	   0.230	   1.400	   1.400	  
Maximum	   5.840	   5.920	   5.630	   5.200	  
Skewness	   0.260	   0.444	   0.185	   0.418	  
Kurtosis	   -­‐1.252	   -­‐1.060	   -­‐1.542	   -­‐1.210	  
Log	  CD4	  Count	   Mean	   2.561	   2.605	   2.547	   2.596	  
Median	   2.631	   2.661	   2.647	   2.679	  
Minimum	   0.780	   0.780	   0.600	   1.040	  
Maximum	   3.170	   3.200	   3.290	   3.250	  
Skewness	   -­‐2.057	   -­‐2.325	   -­‐2.129	   -­‐1.528	  
Kurtosis	   6.393	   9.318	   5.729	   3.982	  
 
 
 4.3 Univariate Analyses 
 4.3.1 Analysis of Main Effects at Baseline 
 HAART Adherence 
The findings of main effects for baseline HAART adherence are presented in 
Table 7 below.  Education and availability of social support was significantly associated 
with HAART adherence at baseline. 
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Table 7: Main Effect On Baseline HAART Adherence 
	  
Term	   OR	   p	  
Sociodemographic	  Variables	   	   	  
Age	   0.983	   0.463	  
Race/Ethnicity	   0.516	   0.122	  
Born	  outside	  of	  the	  US	   0.604	   0.355	  
Language	   0.341	   0.139	  
Marital	  Status	  
Never	  married	  and	  not	  living	  with	  a	  partner	  
1.009	   0.925	  
Married	  and	  living	  together	   1.606	   0.491	  
Married	  but	  living	  apart	   1.005	   0.942	  
Living	  with	  partner	   1.124	   0.732	  
Widowed	   11.577	   0.118	  
Sexual	  Orientation	   0.494	   0.137	  
Have	  Children	   0.724	   0.518	  
Education	  Attainment	  
Less	  than	  HS	  education	  
0.729	   0.463	  
HS	  diploma	  or	  equivalent	   0.315	   0.007	  
Employment	  Status	   1.041	   0.939	  
Family	  income	   1.000	   0.609	  
Receives	  Public	  Assistance	   1.237	   0.582	  
Year	  of	  HIV	  Diagnosis	   0.972	   0.330	  
Last	  CD4	  count	   1.000	   0.584	  
Perceived	  Stigma	   	   	  
Overall	  Stigma	  Score	   1.006	   0.415	  
HIV	  Disclosure	   	   	  
Disclosure	  Proportion	   1.045	   0.939	  
Social	  Support	   	   	  
Mean	  Overall	  Support	  Score	   0.990	   0.953	  
Availability	  of	  Social	  Support	   0.756	   0.039	  
Satisfaction	  with	  Social	  Support	   1.338	   0.245	  
Size	  of	  Support	  Network	   0.952	   0.420	  
 
  
 Viral Load 
The main effects for viral load at baseline are presented in Table 8.  
Race/Ethnicity and being on HAART regimen were found to be significantly associated 
with viral load.    
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Table 8:  Main Effect On Viral Load At Baseline  
	  
Term	   F	   p	  
Sociodemographic	  Variables	   	   	  
Age	   0.131	   0.718	  
Race/Ethnicity	   3.682	   0.057	  
Born	  outside	  of	  the	  US	   0.442	   0.507	  
Language	   0.229	   0.633	  
Marital	  Status	   1.556	   0.176	  
Sexual	  Orientation	   0.243	   0.623	  
Have	  Children	   0.066	   0.797	  
Education	  Attainment	   0.227	   0.797	  
Employment	  Status	   0.187	   0.666	  
Family	  income	   0.107	   0.744	  
Receives	  Public	  Assistance	   0.828	   0.364	  
Year	  of	  HIV	  Diagnosis	   1.253	   0.265	  
On	  HAART	  regimen	   20.177	   0.000	  
Perceived	  Stigma	   	   	  
Overall	  Stigma	  Score	   0.112	   0.738	  
HIV	  Disclosure	   	   	  
Disclosure	  Proportion	   0.757	   0.386	  
Social	  Support	   	   	  
Mean	  Overall	  Support	  Score	   0.032	   0.859	  
Availability	  of	  Social	  Support	   0.254	   0.615	  
Satisfaction	  with	  Social	  Support	   0.501	   0.480	  
Size	  of	  Support	  Network	   0.015	   0.904	  
 
  
 CD4 Count 
Table 9 summarizes the significant the main effects for CD4 count at baseline.  
Employment status, year of HIV diagnosis and being on a prescribed HAART regimen 
were significant associated with CD4 count at baseline.   
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Table 9:  Main Effect On Baseline CD4 Count At Baseline 
	  
Term	   F	   p	  
Sociodemographic	  Variables	   	   	  
Age	   0.161	   0.333	  
Race/Ethnicity	   1.172	   0.281	  
Born	  outside	  of	  the	  US	   0.632	   0.428	  
Language	   0.868	   0.353	  
Marital	  Status	   0.878	   0.497	  
Sexual	  Orientation	   0.513	   0.475	  
Have	  Children	   0.589	   0.444	  
Education	  Attainment	   0.330	   0.720	  
Employment	  Status	   3.582	   0.060	  
Family	  income	   0.730	   0.395	  
Receives	  Public	  Assistance	   0.017	   0.898	  
Year	  of	  HIV	  Diagnosis	   3.148	   0.078	  
On	  HAART	  regimen	   5.338	   0.022	  
Perceived	  Stigma	   	   	  
Overall	  Stigma	  Score	   0.654	   0.420	  
HIV	  Disclosure	   	   	  
Disclosure	  Proportion	   0.059	   0.809	  
Social	  Support	   	   	  
Mean	  Overall	  Support	  Score	   0.382	   0.538	  
Availability	  of	  Social	  Support	   1.557	   0.214	  
Satisfaction	  with	  Social	  Support	   0.037	   0.847	  
Size	  of	  Support	  Network	   0.233	   0.630	  
 
 4.3.2 Repeated Measures Univariate Analyses 
A summary of the results from the repeated measures univariate analyses follows.  
The results of the complete analyses are included in Appendix C.  Table 10 presents the 
following:  (1) the variables included in the repeated measures analyses, (2) the level of 
the Social Ecological model with which each variable corresponds and (3) the variables 
that were positive predictors for HAART adherence, viral load and CD4 count.  
Significant predictors were indicated by a significance level of p less than or equivalent 
to 0.10. 
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Table 10:  Predictor Analysis For Long-Term HAART Adherence 
	  
Social	  Ecological	  
Model	  Level	  
Positive	  Predictors	  
HAART	  
Adherence	  
Viral	  Load	   CD4	  
Education	   Individual	   Yes	   No	   No	  
Employment	   Individual	   No	   No	   Yes	  
Race/Ethnicity	   Individual	   No	   Yes	   No	  
Foreign	  born	   -­‐-­‐-­‐-­‐-­‐-­‐	   No	   No	   No	  
Language	   -­‐-­‐-­‐-­‐-­‐-­‐	   No	   No	   Yes	  
Age	   Individual	   No	   No	   No	  
Family	  Income	   Individual	   No	   No	   No	  
On	  Public	  Assistance	   Individual	   No	   No	   No	  
Marital	  Status	   -­‐-­‐-­‐-­‐-­‐-­‐	   No	   No	   No	  
Sexual	  Orientation	   -­‐-­‐-­‐-­‐-­‐-­‐	   No	   No	   No	  
Year	  of	  Diagnosis	   -­‐-­‐-­‐-­‐-­‐-­‐	   No	   No	   Yes	  
Have	  Children	   -­‐-­‐-­‐-­‐-­‐-­‐	   No	   No	   No	  
Overall	  Stigma	  Score	   Individual	   No	   No	   No	  
Disclosure	  Proportion	   Interpersonal	   No	   No	   No	  
Members	  in	  Support	  Network	   Interpersonal	   No	   No	   No	  
Availability	  of	  Social	  Support	   Interpersonal	   Yes	   No	   No	  
Satisfaction	  with	  Social	  Support	   Interpersonal	   No	   No	   No	  
Mean	  Overall	  Support	   Interpersonal	   No	   No	   No	  
Last	  CD4	  Count	   -­‐-­‐-­‐-­‐-­‐-­‐	   No	   -­‐-­‐-­‐	   -­‐-­‐-­‐	  
On	  HAART	  Regimen	   Individual	   -­‐-­‐-­‐-­‐	   Yes	   No	  
 
 HAART Adherence 
Education (OR=-0.316, p=0.067) and availability of social support (OR=1.323, 
p=0.036) were found to significantly predict repeated measures of HAART adherence.    
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Viral Load 
HAART (β=1.015, p=0.000) and employment (β=-0.553, p=0.085) were found to 
be significant predictors of viral load, over time.   
 CD4 Count 
Being on a HAART regimen (β=0.168, p=0.002), employment status (β=-0.199, 
p=0.004), year of HIV diagnosis (β=-0.010, p=0.055) and language (β=-0.132, p=0.058) 
were significantly associated with CD4 count, over time. 
 4.4 Examination of Study Hypotheses 
The results of the multivariate analyses for HAART adherence, viral load and 
CD4 count are summarized in Table 11 and discussed below. 
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Table 11:  Summary of Hypothesis Testing Outcomes 
Outcome 
Variable	  
Testable Hypothesis Outcome 
No.	   Hypothesis	  
HAART 
Adherence	  
1	   Perceived stigma will be negatively related to HAART adherence. Supported  
2	   Social support and HAART adherence will be positively related. 
Availability of Social Support:  Supported 
Satisfaction with Support:  Not supported 
Overall Support Score:  Not supported 
Size of Support Network:  Not supported 
3	   HIV disclosure and HAART adherence will be positively related. Not Supported 
4	   Perceived stigma, HIV disclosure and social support will have an interactive effect on HAART adherence. Supported 
Viral 
Load	  
5	   Perceived stigma will be positively related to viral load. Supported 
6	   Social support and viral load will be negatively related. 
Availability of Social Support:  Supported 
Satisfaction with Support:  Not supported 
Overall Support Score:  Not supported 
Size of Support Network:  Not supported 
7	   HIV disclosure and viral load will be negatively related. Not supported 
8	   Perceived stigma, HIV disclosure and social support will have an interactive effect on viral load. Not Supported 
CD4	  
9	   Perceived stigma will be negatively related to CD4 count. Supported 
10	   Social support and CD4 count will be positively related. 
Availability of Social Support:  Supported 
Satisfaction with Support:  Not supported 
Overall Support Score:  Not supported 
Size of Support Network:  Not supported 
11	   HIV disclosure and CD4 count will be positively related. Not Supported 
12	   Perceived stigma, HIV disclosure and social support will have an interactive effect on CD4 count. Supported 
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 4.4.1 HAART Adherence 
GEE-based logistic regression model was used to test the following four 
hypotheses for HAART adherence: 
Hypothesis 1: Perceived stigma will be negatively related to HAART adherence. 
Hypothesis 2: Social support and HAART adherence will be positively related. 
Hypothesis 3: HIV disclosure and HAART adherence will be positively related. 
Hypothesis 4: Perceived stigma, HIV disclosure and social support will have an  
  interactive effect on HAART adherence. 
Results are presented in Table 13.  In the test of main effect, satisfaction with 
social support was found to be significantly associated with HAART adherence.  
Specifically, higher levels of satisfaction were associated with lower odds of HAART 
adherence.   
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Table 12:  Significant Effect For Repeated Measures Of HAART Adherence 
	  
Term	   OR	   95%	  CI	   p	  
Randomization	  Assignment	   0.873	   0.386	   1.974	   0.744	  
Time	  Elapsed	   1.001	   0.997	   1.004	   0.742	  
Randomization	  Assignment	  x	  Time	  Elapsed	   1.000	   0.997	   1.004	   0.753	  
Disclosure	  Proportion	   0.013	   0.000	   0.639	   0.029	  
Overall	  Stigma	  Score	   0.962	   0.931	   0.994	   0.022	  
Availability	  of	  Support	   1.495	   1.155	   1.936	   0.002	  
Satisfaction	  with	  Social	  Support	   0.700	   0.512	   0.957	   0.025	  
Mean	  Overall	  Support	  Score	   0.677	   0.427	   1.074	   0.097	  
Last	  CD4	  Count	   0.996	   0.991	   1.000	   0.075	  
Availability	  of	  Support	  x	  Time	  Elapsed	   0.999	   0.997	   1.000	   0.065	  
Disclosure	  Proportion	  x	  Overall	  Stigma	  
Score	  
1.053	   1.012	   1.096	   0.011	  
Mean	  Overall	  Support	  x	  Last	  CD4	  Count	   1.001	   1.000	   1.002	   0.062	  
 
 
Introduction of interaction effects revealed additional significant associations with 
HAART adherence.  There was a significant relationship between availability of social 
support and HAART adherence, although the relationship varied by time.  Higher scores 
for availability of support were associated with greater odds of adherence at baseline, 
120-days and 240-days follow up, however the odds of adherence diminished over time 
(See Figure 5).  The effects were reversed by the 12-month follow-up as increases in 
availability of social support were associated with lower odds of adherence.  
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Figure 5: HAART Adherence By Availability Of Support And Time 
Perceived stigma was also significantly associated with HAART adherence over 
time, although this relationship varied by disclosure (See Figure 6).  Among women who 
had disclosed to less than 50% of their support network, perceived stigma was associated 
with nonadherence to HAART regimen.  For women who have disclosed to at least 75% 
of their support network, perceived stigma was positively associated with adherence.  
Thus, greater disclosure improved the relationship between perceived stigma and 
HAART adherence. 
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Figure 6: HAART Adherence By Perceived Stigma And Disclosure 
Finally, mean overall perceived support was significantly associated with 
HAART adherence, although this relationship varied by stage of disease, as indicated by 
the most recent CD4 count prior to enrollment in the study (See Figure 7).  High scores of 
perceived social support were associated with adherence to HAART therapy among 
women with CD4 counts at or above 536 cells/mL.  For women with CD4 counts of 370 
cells/mL, there was relatively no difference in HAART adherence between women with 
high scores and low scores of perceived social support.  Among women with late stage 
disease (CD4 count at or below 264), higher scores of perceived social support were 
associated with non-adherence.  Although statistically significant, these findings must be 
interpreted with caution.  Because the variables are measured over time, it is unclear if 
the change in time is affected the change in HAART adherence or if changes in the 
variables of interest are, in fact, affected the change in the outcome. 
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 Figure 7: HAART Adherence By Overall Support And Last CD4 Count 
Hypotheses #1, 2 and 3 were not supported.  No significant main effects were 
found between HIV disclosure and HAART adherence or social support and HAART 
adherence.  Additionally, while availability of support was found to have a significant 
main effect, increases in availability of support were associated with decreasing odds of 
HAART adherence.  Hypothesis #4 was supported by this study.  The study findings 
suggest HIV disclosure may improve the relationship between perceived stigma and 
HAART adherence. 
 4.4.2 Viral Load 
A GEE-based linear model was used to test the following four hypotheses for 
viral load: 
Hypothesis 5: Perceived stigma will be positively related to viral load. 
Hypothesis 6: Social support and viral load will be negatively related. 
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Hypothesis 7: HIV disclosure and viral load will be negatively related. 
Hypothesis 8: Perceived stigma, HIV disclosure and social support will have an 
 interactive effect on viral load. 
As a main effect, disclosure proportion, perceived stigma and HAART regimen 
were found to be significantly associated with viral load over time (See Table 14).  
Increases in the proportion of members in the support network who were aware of the 
woman’s HIV status was significantly associated with increases in viral load over time.  
Increases in the overall stigma score were significantly associated with increases in viral 
load over time.  Finally, being on a HAART regimen was associated with decreases in 
viral load. 
Table 13:  Significant Effect For Repeated Measures Of Viral Load 
	  
	  
Term	   β	   95%	  CI	   p	  
Randomization	  Assignment	   0.018	   -­‐0.396	   0.433	   0.930	  
Time	  Elapsed	   -­‐0.001	   -­‐0.003	   0.000	   0.164	  
Randomization	  Assignment	  x	  Time	  
Elapsed	  
0.000	   -­‐0.002	   0.001	   0.546	  
On	  HAART	  Regimen	   -­‐1.072	   -­‐1.389	   -­‐0.755	   0.000	  
Disclosure	  Proportion	   0.854	   0.364	   1.345	   0.001	  
Overall	  Stigma	  Score	   0.005	   0.000	   0.010	   0.058	  
Size	  of	  Support	  Network	   0.040	   -­‐0.024	   0.104	   0.221	  
Time	  Elapsed	  x	  Size	  of	  Support	  Network	   2.15E-­‐4	   -­‐3.21E-­‐5	   0.000	   0.088	  
 
 
Tests of interaction effects revealed one significant interaction.  Size of the 
support network was also significantly associated with viral load.  That relationship 
varied by time (See Figure 8).  
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Size of support network was also associated with an increase in viral load, over 
time.  While only a slight increase was uncovered at baseline, the rate of increase 
worsened as time progressed.  
  
 
  
Figure 8: Viral Load By Size Of Support Network And Time 
 
Hypothesis #5 was supported while hypotheses #6, 7 and 8 were not.  Perceived 
stigma had a significant positive association with viral load.  Contrary to hypothesis #6 
and 7, HIV disclosure and social support were also found to have a positive association 
with viral load.  No significant interactive effects were uncovered between viral load and 
perceived stigma, HIV disclosure and social support. 
 4.4.3 CD4 Count 
A GEE-based linear model was used to test the following four hypotheses for 
CD4 count: 
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Hypothesis 9: Perceived stigma will be negatively related to CD4 count. 
Hypothesis 10: Social support and CD4 count will be positively related. 
Hypothesis 11: HIV disclosure and CD4 count will be positively related. 
Hypothesis 12: Perceived stigma, HIV disclosure and social support will have an  
  interactive effect on CD4 count. 
In the test of main effect, being on HAART therapy and availability of social 
support were found to be significantly associated with CD4 count.  Specifically, women 
on HAART therapy had higher CD4 counts over time than women not on a prescribed 
regimen.  Conversely, women who reported greater availability of social support had 
lower CD4 counts over time than those who reported lower levels of availability of social 
support.  Significant findings for CD4 count are presented in Table 15.     
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Table 14: Significant Effect for Repeated Measures of CD4 Count 
	  
Term	   β	   95%	  CI	   p	  
Randomization	  Assignment	   -­‐0.051	   -­‐0.185	   0.083	   0.458	  
Time	  Elapsed	   1.37E-­‐4	   -­‐1.12E-­‐4	   0.001	   0.467	  
Randomization	  Assignment	  x	  Time	  Elapsed	   2.88E-­‐4	   -­‐3.70E-­‐5	   .001	   0.082	  
On	  HAART	  regimen	   0.115	   0.019	   0.211	   0.019	  
Availability	  of	  Social	  Support	   -­‐0.018	   -­‐0.038	   0.002	   0.074	  
Overall	  Stigma	  Score	   -­‐0.004	   -­‐0.007	   -­‐0.001	   0.015	  
Size	  of	  Support	  Network	   -­‐0.065	   -­‐0.114	   -­‐0.017	   0.008	  
Disclosure	  Proportion	   -­‐0.030	   -­‐0.145	   0.086	   0.611	  
Disclosure	  Proportion	  x	  Time	  Elapsed	   -­‐4.41E-­‐4	   -­‐0.001	   -­‐3.83E-­‐6	   0.048	  
Overall	  Stigma	  Score	  x	  Size	  of	  Support	  
Network	  
0.001	   9.73E-­‐5	   0.001	   0.019	  
 
 
Introduction of interaction effects revealed additional significant associations 
between disclosure and CD4 count, although that relationship varied by time (See Figure 
9).  Increases in the proportion of support network that is aware of the woman’s HIV 
status was associated with decreased CD4 count.  The rate of decrease worsens over time.   
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Figure 9: CD4 Count By Disclosure And Time 
 
The regression model also revealed a positive significant relationship between 
size of social support network and CD4 count among women with higher levels of 
perceived stigma (See Figure 10).  Growth in the size of one’s support network had a 
positive effect on CD4 count among women reporting higher levels of perceived stigma.  
The higher the level of reported perceived stigma, the better the relationship between size 
of support network and CD4 count.  For women reporting lower levels of perceived 
stigma, growth in the size of support network did not positively affect CD4 count.  As 
network size increases, CD4 count decreases over time among women reporting lower 
levels of perceived stigma. 
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Figure 10: CD4 Count By Size Of Support Network And Stigma 
 
Hypotheses #9, 10 and 11 were not supported by this study.  No significant main 
effects were observed for perceived stigma and HIV disclosure.  Additionally, social 
support was found to have a negative association with CD4 count.  Hypothesis #12 was 
supported by this study.  The study findings suggest social support may improve the 
relationship between perceived stigma and CD4 count.  Social support may interact with 
perceived stigma, to buffer or moderate the adverse effects of perceived stigma on HIV 
clinical outcomes.  Thus, in the presence of stigma, women with larger social support 
networks may be protected from poorer health, as indicated by lower CD4 counts. 
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CHAPTER V:DISCUSSION 
 5.1 Summary 
With disproportionately high rates of HIV and AIDS among minority women, 
HAART therapy can dramatically improve the health and quality of life for this 
vulnerable population.  Women, who adhere to their HAART regimen, benefit from 
substantial declines in HIV-related morbidity (Garcia de Olalla et al., 2002; McNaghten 
et al., 1999; Palella et al., 1998; Paterson et al., 2000; Wood et al., 2004).  Many factors 
have been shown to influence HAART adherence among women, including those with a 
history of drug abuse.  Understanding the factors that facilitate and impede HAART 
adherence is critical if HIV-positive women are to benefit from the efficacious treatment 
options available for HIV disease.   
HIV-related stigma, HIV disclosure and social support have been linked to 
HAART adherence and health outcomes in numerous cross-sectional studies.  The 
current HIV literature base, however, lacks research on the independent and interactive 
effects of perceived stigma, HIV disclosure and social support on long-term adherence.  
The purpose of this dissertation was to learn how perceived stigma, HIV disclosure, and 
social support operate together to impact long-term HAART adherence and health 
outcomes among HIV-positive women with a history of drug abuse.   
This dissertation consisted of a secondary data analysis of 171 women enrolled in 
a 4-month randomized controlled intervention study that tested the efficacy of Structural 
Ecosystems Therapy for improving HAART adherence and reducing drug abuse relapse 
and HIV transmission risk behaviors among recently sober HIV-positive women (Feaster, 
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Mitrani, et al., 2010).  During the parent study, data on perceived stigma, HIV disclosure, 
viral load and CD4 count were collected over four time periods.  Self-report HAART 
adherence data was collected at baseline and every other month thereafter. This 
dissertation used data collected at baseline and months 4, 8 and 12 of the parent study.  
Because intervention effect was not the focus of this dissertation, data from the 
intervention and control groups were combined for the purposes of this study.   
Generalized estimating equation (GEE) regression models were fitted for each of 
the outcome variables in this study (HAART adherence, viral load and CD4 count).  
Measures of perceived stigma, HIV disclosure and social support were entered into the 
multivariate models and sociodemographic factors were introduced as covariates.  The 
study variables were introduced individually, starting with the variable with the most 
significant level from the univariate analyses.  Interactions of interest between measures 
of perceived stigma, HIV disclosure and social support were then entered and fitted for 
significance.  Intervention effect was controlled for in each model.  Odds ratios (OR), 
95% confidence interval (CI) and associated p-values were obtained for each predictor in 
the models for HAART adherence and the beta (β), 95% CI and associated p-values were 
obtained predictors in the biological marker models.  A significant level of 0.10 was used 
to account for the modest sample size.   
Findings from this study support a direct adverse association between perceived 
stigma and viral load.  Social support was also directly associated with HAART 
adherence, viral load and CD4 count, although the associations were positive and 
negative depending of the domain of social support that was measured.  No direct 
relationship was observed between HIV disclosure and the study outcomes.  In the test of 
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interactions, both HIV disclosure and social support were found to have a protective or 
buffering effect on the adverse relationship between perceived stigma and HAART 
adherence or its biological markers. 
 5.2 Discussion 
 5.2.1 Findings 
HIV Disclosure 
HIV disclosure was unassociated with HAART adherence, viral load and CD4 
count.  In the test of interaction, however, among women who reported high levels of 
HIV stigma concerns, individuals with higher levels of HIV disclosure had lower CD4 
count.  The relationship goes against the hypothesized relationship between disclosure 
and CD4 count.  It is possible that the women are disclosing due to the progression or 
severity of their HIV disease, as indicated by CD4 count.  This study did not capture 
whether disclosure occurred before or after a poor CD4 count. Ambiguity, with regards to 
the sequence of the experiences, limits interpretation of this finding.  
The impact of HIV disclosure requires further study.  The women in this study 
had significant rates of disclosure.  On average, at least 78% of members in the women’s 
support networks were aware of the participants HIV status.  Perhaps, the impact of 
disclosure varies based on relationship of the potential disclosure recipient (i.e. parent, 
sibling, children, partner, friend).  While this level of data was available, this study did 
not analyze outcomes based on the relationship of the disclosure recipient. 
Perceived Stigma 
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Three decades since the beginning of the HIV epidemic, stigma remains a 
prevailing concern for people living with HIV and AIDS (Bogart, Wagner, Galvan & 
Klein, 2010).  Consistent with previous studies examining the relationship between 
perceived stigma and HAART adherence (Rao, Kekwaletswe, Hosek, Martinez, & F., 
2007; Rintamaki et al., 2006; Sayles, Wong, Kinsler, Martins, & Cunningham, 2009), 
including studies that focused on drug users  (Knowlton et al., 2007; Ware et al., 2006), 
the study findings supported higher HIV stigma concerns was associated with 
nonadherence to HAART therapy.  Likewise, perceived stigma was associated with 
disease severity as defined by viral load and CD4 count.  Higher HIV stigma scores were 
found to predict higher viral load and lower CD4 count.  Interaction effects revealed the 
relationship between perceived stigma and long-term HAART adherence varied by 
disclosure.   Among women who had disclosed to less than 50% of their support network, 
perceived stigma was associated with nonadherence to HAART regimen.  For women 
who have disclosed to at least 75% of their support network, perceived stigma was 
positively associated with adherence.  This suggests the impact of stigma on 
nonadherence is improved with greater numbers of disclosure or awareness of the 
woman’s HIV positive status.   
Social Support 
Social support was found to be significantly associated with all of the study 
outcomes.  The findings, however, indicate that the different domains of social support 
may have both positive and negative effects on HAART adherence and health outcomes.  
This is consistent with the social support literature which documents the role support 
networks play in facilitating and impeding health-promoting and self-care behaviors 
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(Bosworth, Voils, Potter, & Steffens, 2008; Hale, Hannum, &Espelage, 2005; Jackson, 
Tucker, & Herman, 2007; Sayers, Riegel, Pawlowski, Coyne, &Samaha, 2008) and 
impeding health-promoting and self-care behaviors, and ultimately, positive health 
behaviors (Gallant, 2003). 
Social support has both a main and buffering effect on HAART adherence and 
HIV health outcomes. As a main effect, availability of social support was positively 
associated with HAART adherence. This finding is consistent with previous literature 
suggesting the positive influence of social support on HAART adherence (Simoni et al., 
2002; van Servellen & Lombardi, 2005).  As an interactive effect, the size of the support 
network may interact with perceived stigma to buffer the adverse affects of perceived 
stigma on health outcomes.  Specifically, the findings suggest among women who report 
moderate to high levels of perceived stigma, larger social support networks may 
moderate the adverse effects of perceived stigma on HAART adherence.   
 The findings also suggest social support may have no effect or a negative effect 
on HAART adherence and health outcomes.  For example, overall support was found to 
be positively associated with HAART adherence only among healthier individuals or 
individuals, who at the time of enrollment, had a CD4 counts at or above 536 cells/mL.  
For individuals with lower CD4 counts, higher overall mean support was associated with 
non-adherence.  In the study of viral load, availability of social support was associated 
with a negligible decrease in viral load among women who were adherent and was 
associated with a notable increase in viral load among women who were not adherent.  
As with disclosure, this study did not capture the sequence of events or experiences 
related to social support, adherence and disease severity, as indicated by viral load and 
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CD4 count.  In fact, the negative relationships with social support may be a function of 
members of the women’s support network rallying around them as a result of disease 
progression or worsening illness.  Thus, as a woman’s viral load increases, or CD4 
declines, she will likely get sicker, experiencing more symptoms related to their HIV 
disease or other illness caused by a compromised immune system.  Consequently, the 
woman may muster more support and more family and friends may rally around the 
woman providing greater support.  In the absence of the sequencing of the woman’s 
experiences, it is difficult to ascertain if, in fact, social support is led to the observed 
outcomes or the woman’s health status helped garner greater support. 
Negative effects of social support may be better understood by disentangling the 
interpersonal dynamics of social networks.  Social support networks are complex 
structures with bidirectional, interpersonal and dynamic interactions between and among 
its members.  Some studies have examined the intricacies of family and social ties in 
order to understand social influences on health promoting or self-care behaviors, 
specifically among African Americans.  According the US Census (2010), the number of 
African American households headed by women exceeds that headed by married couples.  
Additionally, African Americans are more likely to live with and care for their children 
or grandchildren than any other racial group (Warren-Findlow & Prohaska, 2008).  
Additionally, the size of the support group is usually larger for African Americans 
compared to other racial groups (Bosworth et al., 2008).  Membership in large family or 
social support networks, however, does not guarantee receipt of support.  On the 
contrary, large networks may subject African Americans to more interpersonal conflict 
and stressors, which hinder health-promoting behaviors (Owen, 2003).  Larger networks 
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may also imply an expectation, self-imposed or otherwise, to support or care for others as 
opposed to receiving support (Samuel-Hodge et al 2005, McEwen, 2011).  Adopting this 
caregiving role may hinder HAART adherence and positive health outcomes as the 
caregiver may place the needs of the family before her own health care needs.   
By limiting social support to a linear, unidirectional phenomenon limits the 
context in which social support is both received and provided by women in this study.  
The principal investigators of the SETA study recognize the bi-directional and dynamic 
nature of social support networks and completed a companion study concurrently with 
the SETA study, which targeted members of the women’s social support network.  
Among other constructs, the study examined social support as reported by the members 
of the woman’s support network.  Data from that study is available and could be used to 
further explore social support networks for the women in this study.  Investigating the 
interpersonal dynamics of social support, however, did not fall within the scope of this 
dissertation. 
Study findings also point indicated that the negative relationship between 
perceived stigma and HIV-related health outcomes decreased with increases in the 
proportion of the support network that was of the woman’s HIV status.  Thus, the 
negative relationship between perceived stigma and HAART adherence and HIV-health 
outcomes may also be improved with HIV disclosure.  Given the predominate focus on 
African American women in this study, these findings suggest that HIV disclosure and 
social support among African American woman may play an important role in improving 
HAART adherence and HIV-related health outcomes, particularly when these women 
perceive or fear stigma related to their HIV disease. 
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 5.2.2 Limitations Of Study 
Several limitations must be considered when interpreting the study findings.  
First, the modest sample size may not fully account for the variability in experience of 
perceived stigma, HIV disclosure, social support and HAART adherence among the 
general HIV-infected population.  Second, the use a relatively small convenience sample 
during the parent study limits the generalizability of the study findings to similar 
populations.  Third, without a comparative sample of HIV positive women with no 
history of substance abuse, it is difficult to link the findings of this study to drug use or 
dependence.  Fourth, the data used for this study was collected five to nine years ago, 
raising the possibility that some characteristics of the population may have changed, 
limiting the generalizability of the study findings to future populations.  Also, while 90% 
was used as the adherence cut-off for this study, 95% adherence is the ideal cutoff for 
optimal virologic suppression of HIV disease.  Additionally, HAART adherence data was 
based on self-reports, which typically overestimates actual medication adherence (H. Liu 
et al., 2001; Martin et al., 2009; Wagner & Rabkin, 2000).  Bivariate analyses revealed 
agreement between the transformed viral load variable and self-reported adherence, 
bolstering the reliability of the self report data.  There was not agreement between CD4 
and adherence data, although the skewness the CD4 count data may account for this 
finding.     
While GEE regression analysis was a feasible technique for this study, structural 
equation modeling (SEM) may help further advanced understanding of how perceived 
stigma, HIV disclosure and social support jointly influence HAART adherence, viral load 
and CD4 count.  SEM tests overall model rather than individual coefficients.  SEM also 
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allows for test of multiple outcome variables in one model, a useful feature in studies like 
this where outcomes are naturally related and a variable can be both an outcome and a 
predictor.  Unlike regression, SEM accounts for reciprocal paths for specific 
relationships, which provides greater insight than one-way causal flow. Additionally, 
SEM also accounts for both the direct influence and unobserved common cause of 
predictor variables on the outcome variable.  Unobserved or latent variables are inferred 
by the relationships or correlations among the study variables included in the model. 
 5.3 Recommendations 
 5.3.1 Implications For Public Health Practice 
The research findings suggest that public health practitioners and medical 
providers should make concerted efforts to understand the dynamics of the family and 
social support networks.  Family-centered interventions may help support members 
understand the assistance HIV-positive women may need or expect while helping the 
women learn to use her support network most effectively to manage her disease.  
Discussions about support and disclosure may become a part of the HIV medical visit. 
Adverse effects of perceived stigma highlights the need for continued culturally-
sensitive education and training about HIV and AIDS.  The public health community 
should take steps to mitigate HIV-related stigma at the provider and community levels.  
In healthcare settings, medical providers should address concerns about unintended 
disclosure, HIV stigma and HAART adherence with patients living with HIV and AIDS.  
Thus, medical providers will need trainings to help them assess disclosure and stigma 
concerns among their patients.  For patients with great concerns about disclosure and 
stigma, providers may consider discussing various regimen options and soliciting patient 
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input on the treatment schedule that would minimize risk of exposure when taking 
medications.  Diminished risk of unintended disclosure may temper stigma concerns and 
allow strict adherence to HAART treatment.  Within the community, public health 
education efforts, focused on spreading knowledge and addressing misconceptions about 
transmission, are essential to eliminate fear among the general public and discrimination 
against those living with HIV disease.  Education should be conducted in various 
community settings including schools and churches in order to ensure education 
messages reach and diverse segments of the population. 
 5.3.2 Recommendations For Further Research 
While findings from this dissertation support the proposition that perceived 
stigma, HIV disclosure and social support do operate together to impact HAART 
adherence and health outcomes, further study is warranted.  The study hypotheses should 
be re-examined using SEM models, which may reveal more complex relationships 
between the study variables and latent variables, not uncovered during this study.  
Additionally, the parent study was a comprehensive investigation, which collected 
extensive data that may be used for future analyses.  The disclosure and social support 
data, for example, included information about the individuals to whom the woman 
disclosed and the individual who comprised the woman’s social support network.  This 
information included the gender, age, relationship and living status (i.e. whether the 
individual lived with the women).  Including the characteristics of a woman’s disclosure 
targets and social support networks will provide a more in-depth understanding of the 
disclosure targets and social support compositions that are most beneficial to HAART 
adherence among HIV-positive women. 
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The lack of longitudinal studies of adherence behaviors among woman dually 
diagnosed with HIV and drug use underscores the importance of continuing long-term 
investigation into HAART adherence among this vulnerable population.  Large scale, 
longitudinal investigations are needed to better explore the distinct and interactive impact 
of perceived stigma, HIV disclosure and social support on long-term HAART adherence 
and health. 
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Background: Substance abuse in women with HIV/AIDS overshadows other priorities, including health
care. Substance abuse may cause women to avoid health care systems and not adhere to their medication
regimen.
Methods:A randomized controlled trial tested the efﬁcacy of Structural Ecosystems Therapy (SET) relative
to a psychoeducational Health Group (HG) in 126 HIV+ women in recovery. SET, a 4-month intervention,
focused onbuilding family support for relapse prevention andHIVmedication adherence. Over 12-month
follow-up, women were assessed for drug use and medication adherence every 2 months; CD4 T-cell
count and HIV viral load were assessed every 4 months.
Results: Levels of drug use did not differ by condition. There was a signiﬁcant difference in curvature of
the rates of change in drug use with SET increasing and then decreasing and HG decreasing and then
increasing. Women in SET were more likely to increase substance abuse services in response to relapse
121and separate fromdrug using householdmembers thanwerewomen inHG. These two changes explained
thedecline in druguse observedwithin SETbetween6 and12months. SET showeddeclines inmedication
adherence but increases in CD4 T-cell count relative to HG. The increase in CD4 T-cell count in SET was
related to increasing proportions of women in SET taking antiretroviral medications.
Conclusion: The results of the trial weremixed.Women in SET did not showbetter drug use ormedication
adherence outcomes, but did show improvement in CD4 T-cell count and theoretical mechanisms of
action on drug relapse.. Introduction
Women, particularly women of color, are at an increased risk
or HIV infection and AIDS. The Center for Disease Control and Pre-
ention (CDC, 2008) estimates that women account for 26% of all
ew HIV/AIDS diagnoses. In 2005, HIV infection was the leadingPlease cite this article in press as: Feaster, D.J., et al., A randomized controlled
and substance abuse relapse prevention. Drug Alcohol Depend. (2010), doi
ause of death for African American women aged 25–34 years and
he fourth leading cause of death for Hispanic women aged 35–44
ears (National Institute on Drug Abuse, 2008).
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Drug abuse is inextricable from HIV/AIDS (National Institute on
Drug Abuse, 2006). Injection drug use underlies 1 in 5 new HIV
diagnoses among women (CDC, 2005). Women who use cocaine or
other non-injection drugs have higher risk from selling or trading
sex for drugs (Edlin et al., 1994). In addition, high-risk behaviors are
more likely under the inﬂuence of drugs or alcohol (Leigh and Stall,
1993). Physical and emotional problems of HIV are compounded by
legal and social consequences of substance use (Boyd and Holmes,
2002). Substance abuse often overshadows other priorities, includ-
ing health care and adherence to HIV medication regimens (García
and Côté, 2003; Lucas et al., 2001; Sherer, 1998; Turner et al., 1998;trial of Structural Ecosystems Therapy forHIVmedication adherence
:10.1016/j.drugalcdep.2010.04.017
Williams et al., 2000).
Most interventions targeting HIV medication adherence are
individual in nature (Remien et al., 2005). Individual modalities
may be less efﬁcaciouswith poor, inner-cityminorities (Markowitz
et al., 2000), likely fromnot considering cultural context (e.g., racial
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iscrimination, poverty-strickenneighborhoods). Family, in partic-
lar, is a source of support for African Americans and Hispanics
Boyd-Franklin, 1989; Burns et al., 2005; Smith et al., 2001), who
ome from a collectivist tradition with strong family inﬂuences
n decision-making and behavior. But family problems may be
elated to drug use. Iraurgi-Castillo et al. (2004) linked drug use
iagnosis to higher family stress, lower family satisfaction, less
ommunication, and fewer family resources. Conﬂicts with family
nd drug-using partners often present unique challenges to sobri-
ty (Grella et al., 2003). Some women may use drugs to cope with
ainful feelings, stress, and family conﬂicts. Drug-using partners
ay increase access to substances, paraphernalia, and other cues,
s well as encourage use (Moos, 2007).
We know of no empirically supported interventions speciﬁ-
ally designed for women with HIV/AIDS in recovery. Structural
cosystems Therapy (SET; Mitrani et al., 2009a,b,c) is a family
ased intervention for poor inner-city HIV+ women targeting psy-
hosocial factors (e.g., reduced family stress and increased family
upport) associated with progressions in HIV symptoms. In a pre-
ious randomized clinical trial, SET showed efﬁcacy in reducing
sychological distress and family-related irritation (Szapocznik et
l., 2004), lowering rates of relapse (Feaster et al., 2010a), and
ncreasing medication adherence (Feaster et al., 2010b). The cur-
ent study extends previous ﬁndings by testing the efﬁcacy of SET
or improving HIV medication adherence and reducing relapse as
ompared to aHealthGroup (HG) intervention forwomen in recov-
ry.
Twoprimaryhypotheseswere tested. First,women inSETwould
ave lower substanceuse thanwomen inHG.Second,women inSET
ould have greater HIV medication adherence than women in HG.
edication adherence combined four measures of both pill-taking
ehavior and biological consequences of pill-taking behavior: tak-
ng antiretroviral medications, self-report percentage of pills taken
f taking medications, CD4 T-cell count, and HIV viral load. In addi-
ion, we tested potential mediators of treatment effects. Family
issatisfaction, living with a substance user, and drug treatment
ervice utilizationwere considered as potentialmediators of effects
n drug use. Family dissatisfaction and medical service utilization
ere considered as mediators of effects on HIV medication adher-
nce. Finally, the two behavioral components of adherence were
onsidered as mediators of CD4 T-cell count and HIV viral load.
. Methods
.1. Participants
To be eligible for the current clinical trial, women had to have been HIV-1
eropositive and (1) be prescribed antiretroviral medication, (2) have a viral load
ver 100,000 or CD4 T-cell count under 350, or (3) have a diagnosis of any AIDS-
eﬁning disease. Therefore participants were either taking HIV medications or at a
tage when HIV medications would be advised. Additional inclusion criteria were:
t least 18 years of age, meet the DSM-IV criteria for substance use diagnosis within
he last year (with cocaine as either the primary or secondary drug of abuse), will-
ng to disclose their HIV status to at least one health care professional, and have at
east one family member agree to enroll in a companion study of family interven-
ion mechanisms. Recruitment for the study was from 2003 until 2007. Fig. 1 shows
articipant ﬂow through the study.
.2. Structural Ecosystems Therapy
SET is a family-ecosystemic intervention that targets the HIV+ woman’s social
nvironment by strengthening adaptive interactions and reducing maladaptive
nteractions within the family and between the woman, family and other sys-
ems (e.g., health care, substance abuse treatment, religious institutions, neighbors)
o improve the woman’s psychosocial functioning and health (see Mitrani et al.,Please cite this article in press as: Feaster, D.J., et al., A randomized controlle
and substance abuse relapse prevention. Drug Alcohol Depend. (2010), doi
009a,b,c). In this application of SET, therapists were instructed to (1) strengthen
amily support for health care and medication adherence, (2) draw clear bound-
ries between the woman and any substance-using social contacts, and (3) develop
plan to address potential relapse that included family member assistance with
ccess to drug treatment services to either prevent or respond to a relapse. SET ses-
ions were completed in the home, therapist’s ofﬁces, or other locations based on PRESS
ependence xxx (2010) xxx–xxx
client choice. In general, SET sessions were weekly for 50min for up to 4 months
after randomization.
2.3. The HIV Health Group (attention control)
The HIV Health Group was incorporated to control for common factors in
therapy, e.g., attention, therapist qualities, or client expectancies. Adapted from
Hartﬁeld’sWellnessManual (Baker et al., 2003),HGrepresenteda standardpsychoe-
ducational intervention for HIV+ women. Topics included medication adherence
and HIV transmission risk reduction. All HG sessions were conducted biweekly at
the ofﬁces of the study for a total of 8, 90-min sessions.
2.4. Interventionists
There were different therapists in each condition. In the HG, facilitators were
one African American female certiﬁed addiction counselor and one Hispanic female
master’s level social worker with 9.6 (SD=7.2) years experience. In SET, therapists
were two African American women and one Hispanic woman; all were master’s
level social workers with 12.0 (SD=14.0) years experience.
2.5. Procedure
2.5.1. Pilot. Procedureswerepilotedwith 30women (15 in each condition)without
random assignment, i.e., to train intervention and assessment staff, and to ﬁnalize
modiﬁcations to the SET manual to incorporate relapse prevention and medication
adherence. No data on pilot subjects are presented.
2.5.2. Randomized clinical trial. The IRB approved protocol included manuals for
both interventions and all study procedures. Staff described study procedures to
potential participants in a private ofﬁce. After the woman had a chance to ask
any clarifying questions, informed consent was obtained. Following an approxi-
mately two hour assessment, the study coordinator assigned women to one of the
two conditions using computerized urn randomization (Wei and Lachin, 1988), bal-
ancing for age (±40 years), ethnicity (Hispanic, African American, and other), HIV
medication status (currently taking medications or not taking but appropriate for
medications), and level of last drug treatment (residential and day treatment or out-
patient). Women could receive up to $330 for participation in assessments ($40 at
baseline, $15 at 2 months, $55 at 4 months, $20 at 6 months, $75 at 8 months, $25 at
8 months, and $100 at 12 months). Assessors were blind to treatment assignment.
Treatment and assessment staff were in physically separated ofﬁces. The General
Clinical Research Center completed blood draws and medical histories. To conserve
resources depleted by a longer thanplanned recruitment period, assessments at 2, 6,
and8monthsweredropped in the last year of the study. Resulting sample sizeswere
Baseline =126, Month 2=118, Month 4=116, Month 6=90, Month 8=105, Month
10=70, Month 12=99 (see Fig. 1). Estimation procedures allowed for unbalanced
data and all collected data were utilized in analysis. The study was monitored every
6 months by a departmental quality assurance unit administered independently of
the research study. Monitoring was designed to prevent drift in procedures, ensure
full human subjects and regulatory compliance, and verify completion and accuracy
of case report forms. Reporting was to the principal investigator and local IRB.
2.6. Measures
2.6.1. Fidelity to treatment protocol. A total of 291 randomly selected videotaped
sessions (221 from SET and 70 from Health Group) were rated on a 5-point scale,
from 1 (not at all/poor) to 5 (extensively/excellent), for ﬁdelity to therapy protocol.
Two raters were initially trained to an inter-rater reliability coefﬁcient of .80 with
the rating supervisor (MSR), and retrained every 6 months to prevent drift. Over-
all inter-rater reliability was .98 for the SET sessions and .96 for the Health Group
sessions. SET sessions were rated on the following ﬁve domains: joining, tracking
and eliciting diagnostic enactments, creating a context for change, restructuring the
family system, and content focus of therapy session. Cronbach’s ˛ of the ﬁrst four
ranged from .76 to .88. Four behaviors (joining, promoting group cohesiveness, act-
ing as a “switchboard,” and wrapping up) were rated for HG sessions. Additionally,
the extent that assigned topics were covered was rated separately for each of the
eight group sessions. Internal consistency was not anticipated because the HG did
not have theoretically prescribed behaviors.
2.6.2. Substance use. DSM-IV substance use diagnoses were obtained using the
Composite International Diagnostic Interview (CIDI 2.3, World Health Organization,
1997). Reported days of use of alcohol and illicit drugs in the past 30 days from the
Addiction Severity Index (ASI; McGahan et al., 1986) were summed into a single
substance use composite. Self-report substance use was correlated with urine drug
screen results at each assessment (rs = .20–.43). Substance use was analyzed using
122d trial of Structural Ecosystems Therapy forHIVmedication adherence
:10.1016/j.drugalcdep.2010.04.017
a negative binomial distribution (Atkins and Gallop, 2007).
2.6.3. Medication adherence.
2.6.3.1. Self-report adherence. Self-report adherence was measured with the AIDS
Clinical Trial Group Adherence Interview Questionnaire (Chesney et al., 2000).
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omen listed HIV medications, number of pills taken, and the number pills missedPlease cite this article in press as: Feaster, D.J., et al., A randomized controlled
and substance abuse relapse prevention. Drug Alcohol Depend. (2010), doi
n each of the previous 4 days. For analysis self-report adherence was measured in
wo ways. First, it was dichotomized as adherent (taking at least 90% of the pre-
cribed dose) and non-adherent (taking less than 90% of prescribed doses) as a com-
romise between the 95% adherence recommended by the World Health Organiza-
ion and more recent recommendations of 80–90% adherence for acceptable sup-
ression of viral replication (Bangsberg, 2006; Parienti et al., 2008). Second, it wasct ﬂow diagram.
dichotomized as taking versus not taking HIV medications to test effects on medi-trial of Structural Ecosystems Therapy forHIVmedication adherence
:10.1016/j.drugalcdep.2010.04.017
cation initiation. A binomial distribution was used for both outcomes in analyses.
2.6.3.2. HIV viral load. HIV Viral Load Blood HIV-1 RNA levels were obtained using
reverse transcriptase polymerase chain reaction (RT-PCR) by Rochewith a detection
range of 400–750,000 copies/ml. Viral loadwas log-transformed for all analyses, and
was approximately normally distributed.
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Table 1
Participant characteristics at basline.
Characteristic SET (n=59) HG (n=67)
M or N SD or % M or N SD or %
Age 44.1 0.9 42.2 1.0
Less than high school education 41 73.2% 53 79.1%
Hispanic 8 13.6% 7 10.5%
African American 42 71.2% 58 86.6%
Never married, not cohabitating 19 33.9% 34 50.8%
Household income $7796 1025 $7551 933
CD4-cell count 467.7 36.3 519.3 39.6
Log viral load 3.03 0.18 2.94 0.17
Years since HIV diagnosis 9.4 0.8 10.4 0.7
Years of substance abuse 22.7 1.3 21.2 1.2
Cocaine dependence 57 96.6% 62 92.5%
124ARTICLEModelAD-3816; No.of Pages8
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.6.3.3. CD4 T-cell count. T-cell Subset (CD4/CD8) lymphocyte phenotypes were
btained using BD Biosciences FACSalibur 4-color ﬂow cytometer and monoclonal
ntibodies for lympohcytes, T cells, T-helper and suppressor cells. CD4 T-cell count
as approximately normally distributed.
.6.4. Mechanisms of action.
.6.4.1. Family Dissatisfaction. Family and support dissatisfaction was measured
sing a subscale of the 29-item Feetham Family Functioning Survey (FFFS) (Roberts
nd Feetham, 1982), which asks respondents to indicate the amount of time they
pend and that they would like to spend with family, friends, and healthcare
roviders on a 7-point Likert scale (1 = Little to 7=Much). Family dissatisfaction
as the gap score, calculated by summing differences between desired and actual
nteractions. Cronbach’s ˛ for family dissatisfaction was .88.
.6.4.2. Livingwitha substanceuser. The fullASIprovided thewoman’s reportof cur-
ently living with someone using alcohol or drugs. These two items were combined
nto an indicator of living with someone that uses substances.
.6.4.3. Service use. Dosage of in-study services was collected from study records.
ervices from outside of the study were assessed by a form that enumerated vari-
us potentially supportive services: psychosocial (including drug abuse treatment),
ocial, religious/spiritual, and medical. Analyses focused on the number of medical
nd drug abuse treatment services.
.7. Analytic plan
Each hypothesis was tested using a separate intent-to-treat (ITT) Generalized
stimating Equations (GEE) analysis. For all analyses the autoregressive (AR1) cor-
elation structure was selected after comparing the ﬁt of alternative structures.
rimary analyses were conducted with the full sample for the ﬁve outcomes: sub-
tance use, taking antiretroviral medications, self-reported medication adherence,
D4 T-cell count, and HIV viral load. Fit of linear and quadratic models for each out-
omewas testedusing the quasi-likelihoodunder the independencemodel criterion
QIC), with lower values indicating better ﬁt; the best ﬁtting models are presented.
or models with more than a linear time trend, time was coded orthogonally to
void collinearity of polynomial trends (Hedeker and Gibbons, 2006).
.7.1. Tests of mediation. The second stage of the analysis was to test whether
hanges in (1) family dissatisfaction, living with a substance user, or outside drug
reatment services mediated treatment effects on substance use and (2) family
issatisfaction and amount of medical services mediated effects on medication
dherence. To further understand the relationship between the variousHIVmedica-
ion adherence variables, the two self-report variables were examined as potential
ediators of effects on CD4 T-cell count and viral load. Initially each of these poten-
ialmediatorswas examined for differences across condition using theGEEmethods
escribed above. The test of mediation for variables measured at four timepoints
ested the product of the pathways from the intervention to the slope of the hypoth-
sized mediator and from the slope of the mediator to the slope of the outcome. For
ediators that were measured at seven timepoints, a cross-lagged model was used.
n both cases the statistical test utilized the delta-method standard errors for this
roduct (Muthén and Muthén, 1998–2007). Additionally, due to a small difference
n baseline rates across conditions, we tested (1) if living with a substance user
oderated treatment effects on substance use and (2) for moderated-mediation of
ffects on substance use.
.7.2. Sample size determination. Sample size was determined using a program
escribed by Hedeker et al. (1999). Analyses showed that a sample of 134 women
ould provide over 80% power to uncover a medium-sized difference between con-
itions (0.50 SD). With N=126, there was over 80% power to uncover a moderate
ffect size (0.53 SD; Cohen, 1988).
. Results
.1. Sample characteristics
As shown in Table 1, women were relatively low-income and
ostly minority, with relatively severe substance use disorders.
here were no signiﬁcant differences between conditions at the
01 level (30 tests were conducted).Please cite this article in press as: Feaster, D.J., et al., A randomized controlle
and substance abuse relapse prevention. Drug Alcohol Depend. (2010), doi
.2. Fidelity to treatment protocol
Ratings of SET sessions showed fair to average (∼3)ﬁdelity (join-
ng, M=3.89, SD=0.81; eliciting diagnostic enactments, M=3.72,Alcohol dependence 41 69.5% 51 76.1%
Cannabis dependence 19 32.2% 34 50.8%
Opioid dependence 10 17.0% 18 26.9%
Dependent on multiple substances 44 74.8% 56 83.6%
SD=0.78; creating context for change, M=2.58, SD=1.01; restruc-
turing, M=2.41, SD=0.82). Over a third (38.1%) of sessions
addressed systems outside of the family at least minimally; 24.0%
addressedmedication adherence, and 48.9% substance use/relapse.
Ratings of HG sessions showed above average ﬁdelity (joining;
M=4.13, SD=0.68; promoting cohesiveness, M=3.31, SD=1.01;
acting as a switchboard, M=4.86, SD=0.39; wrapping up, M=3.17,
SD=1.38; topic coverage, M=4.20, SD=0.61).
3.3. Engagement and dose of intervention
Engagement was deﬁned as attendance at two or more sessions
(Prado et al., 2002; Mitrani et al., 2003). Of the 126 women ran-
domized to SET or HG, 59.5% (n=75) were successfully engaged.
Engagement was not different between SET (55.9%) and HG (62.7%)
(2 (1, N=126) =0.12, p= .44). In SET, 49.2% of cases also had fam-
ily members engaged. Mean session length in SET was 71.83min
(SD=28.02). HG sessions were approximately 90min. For the
women engaged, the number of sessions was greater in SET
(M=9.12, SD=4.11) than HG (M=5.50, SD=1.84), F(1, 75) =26.01,
p< .001.
3.4. Substance use
We found a non-signiﬁcant Time×Treatment interac-
tion (B=0.17, SE =0.13, p< .20). There was a signiﬁcant
Time2 ×Treatment (B=−0.27, SE =0.11, p< .02), with substance
use, shown in Fig. 2A.
3.5. Medication adherence
The probability of taking prescribed HIV antiretroviral medica-
tions was not signiﬁcantly different across conditions. However,
the model predicted an increase in SET from 79% taking pre-
scribed medications at baseline to 88% at 12 months whereas
HG started at 87% and increased to 88% at 12 months. There
was a signiﬁcant Time×Treatment interaction (B=−1.14, SE =0.57,
p< .05) for % pills taken, shown in Fig. 2B. There was also a sig-
niﬁcant Time×Treatment interaction (B=77.02, SE =30.18, p< .05)
for CD4 T-cell count, but a non-signiﬁcant Time2 ×Treatment
(B=−7.22, SE =19.04, ns), shown in Fig. 2C. We found no signiﬁcant
Time×Treatment effect onHIV viral load, although the direction of
change was consistent with CD4 T-cell results.d trial of Structural Ecosystems Therapy forHIVmedication adherence
:10.1016/j.drugalcdep.2010.04.017
3.6. Potential mediators of substance abuse results
3.6.1. Family dissatisfaction. The Time×Treatment interaction
was not signiﬁcant, but the Time2 ×Treatment was signiﬁcant
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125ig. 2. Estimated trajectories of substance use days, the proportion of medication
dherence, and CD4-cell count for women in SET and the Health Group.
B=−8.87, SE =4.12, p< .04), shown in Fig. 3A. Family Dissatisfac-
ion was not related to substance use; therefore there was no
vidence of mediation. There was no evidence of family dissatis-
action as a mediator of the effect of SET on medication adherence.
.6.2. Living with a substance user. There was a non-signiﬁcant
rend in the probability of living with a user at baseline (B=0.83,
E =0.46,p< .08),withmorewomen in theSETcondition livingwith
substance user. As shown in Fig. 3B, the probability of living with
substance user declined signiﬁcantly in SET versus an increase
n Health Group (B=−0.35, SE =0.12, p< .004). The linear trajec-
ory of living with a user was related to the quadratic component
f substance use (B=13.5, SE =6.5, p< .04), indicating that women
ith decreased likelihood of living with a user also had decreases
n drug use. A test of treatment effects on the quadratic component
f drug use mediated by the probability of living with a user was
igniﬁcant (Indirect Effect=−.50, SE =0.23, p< .03), suggesting that
ecreases in substance use in SET worked through the decreased
robability of living with substance users.
.6.3. Service use. There was a signiﬁcant difference in the
uadratic trajectories of drug treatment services across condition
B=−.74, SE =0.25, p< .003), as shown in Fig. 3C. As seen in the
utoregressive cross-lagmodel in Fig. 4, therewas a signiﬁcant neg-
tive effect of SET on drug use at the end of the study that works
hrough SET’s increase in participation in outside substance abuse
reatment at 6 months (Indirect Effect=−0.22, SE =0.11, p< .05).
here was no treatment effect on medical services, and therefore
o mediation with medication adherence.Please cite this article in press as: Feaster, D.J., et al., A randomized controlled
and substance abuse relapse prevention. Drug Alcohol Depend. (2010), doi
.6.4. Medication adherence. We found no evidence that % pills
aken mediated the treatment effect on CD4 T-cell count. Although
reatment differences in the probability of taking medication were
ot signiﬁcant, therewasweakpositive relationshipbetweenprob-Fig. 3. Estimated trajectories of family dissatisfaction, the probability of living with
a substance user, and drug treatment visits for women in SET and the Health Group.
ability of taking meds to CD4-cell count (B=21.5, SE =13.0, p< .10).
In addition, the treatment effect on CD4-cell count was no longer
signiﬁcant when the slope of taking medications was controlled.
However, the product of pathways was not signiﬁcantly different
from zero suggesting no mediation.
3.6.5. Moderation analyses. The trend toward baseline differences
warranted further examination of whether living with a user
at baseline moderated intervention effects. There were signiﬁ-
cant Time×Treatment× Living with a Substance User (B=−2.28,
SE =0.96, p< .05), and Time2 ×Treatment× Living with a Substance
User (B=2.47, SE =0.89, p< .01) effects; the moderation effect is
shown in Fig. 5. Due to the complexity of the resulting model, we
did not examine a single moderated-mediation model. However,
we examined the relationship between treatment and living with a
substance user at baseline on drug treatment services at 6 months.
Treatment had a signiﬁcant effect on drug treatment services for
womennot livingwith a user at baseline (B=1.40, SE =0.69, p< .05).
The relative effect of SET was larger for women living with a sub-
stanceuser at baseline (B=5.47, SE =2.27,p< .02). This suggests that
women inSEThadgreater drug treatment services at 6months than
those in HG, and in SET, women living with a user at baseline also
had even greater drug treatment services than those not livingwith
a user.trial of Structural Ecosystems Therapy forHIVmedication adherence
:10.1016/j.drugalcdep.2010.04.017
4. Discussion
This trial targeted urbanHIV+woman recently out of drug treat-
ment, a population worthy of intervention for relapse prevention
ARTICLE IN PRESSGModelDAD-3816; No.of Pages8
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126ig. 4. Mediation of SET’s decrease in substance use days by engagement with trea
rior substance use to later substance use treatment were not statistically signiﬁca
nd HIV-associated health issues as shown by pre-intervention
haracteristics. Over one-third (38.9%) of women either reported
ubstance use or had a positive urinalysis. Almost a ﬁfth (16.8%)
ere not taking HIV medications, despite laboratory values sug-
esting the beneﬁt of medications. Of those on medications, 13%
eported poor adherence. The results of comparisons of the two
nterventions aremixed.However, it is important to remember that
or ethical reasons both were active interventions directly target-
ng the outcomes. The remainder of this discussion highlights the
esults, reviews the issues that need to be addressed to improve
ftercare interventions for this population, and concludeswith rec-
mmendations and limitations.
.1. Drug use
Although reported levels of substance use were relatively lowPlease cite this article in press as: Feaster, D.J., et al., A randomized controlle
and substance abuse relapse prevention. Drug Alcohol Depend. (2010), doi
hroughout the study, relapse was still a major concern for these
omen. Average reported substance-using days were about 4 per
onth for the Health Group and about 3 per month for SET. How-
ver more than half (56%) of women in both conditions either
ig. 5. Moderation of estimated substance use days by initially living with a sub-
tance user for women in SET and the Health Group.services. Note: only signiﬁcant standardized pathways are shown; pathways from
reported substance use or had a positive urine drug screen 12
months post-randomization. These numbers are consistent with
the chronic nature of substance use disorders.
There were no signiﬁcant differences in levels of substance use
between conditions. However, there was evidence that theoretical
mechanisms of change were active. SET had signiﬁcant decreases
in the proportion of women living with an active substance use
user, and drug treatment service utilizationwas greater in SET than
HG. These differences are consistent with the SET protocol’s estab-
lishment of ﬁrm boundaries with substance-using contacts and
development of a relapse plan with both the recovering woman
and her (non-using) family members. Family-initiated interven-
tion to re-engage the woman in drug treatment may be part of
the reason for the slight increase in family dissatisfaction observed
in follow-up. Women in SET showed an increase in substance use
in the middle of follow-up, then a decline at the end of follow-up.
Initial increases in drug use by women in SET were likely driven by
those entering the study livingwith a substance user. For some rea-
son (perhaps because they happened to come frommore restrictive
drug treatments than women in HG who were initially living with
a user), at baseline women in SET living with a user had extremely
low levels of substance use relative to HG women. Later declines in
drug use of women in SET are likely related to declines in the prob-
ability of livingwith an active substance user. Furthermore,women
in SET had increased participation in drug treatment services after
a relapse, and those living with a substance user at baseline were
even more likely to utilize drug treatment services.
4.2. Medication adherence
Adherence results seem inconsistent. Reported medication
adherence declined for women in SET relative to women in HG, but
CD4-cell count increased for women in SET relative to the decline
for women in HG. Higher levels of adherence should be associatedd trial of Structural Ecosystems Therapy forHIVmedication adherence
:10.1016/j.drugalcdep.2010.04.017
with lower HIV viral loads and increased immune function. How-
ever, falling slightly below90% adherencemay not havemuch of an
effect on viral load (and in turn CD4-cell count). In addition, a num-
ber of the women in SET not taking HIV medications at baseline
did begin taking them during the study. Although the mediation
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odel was not statistically signiﬁcant, there was some indication
hat the increase in the proportion taking medication was related
o increased CD4-cell count.
This increase in the numbers taking antiretroviral therapy may
e important from a public health perspective. Guidelines for ini-
iation of antiretroviral therapy have changed to starting therapy
arlier in the course of infection (Zolopa, 2010). This is in part
ue to new evidence of health beneﬁts to the HIV+ individual of
tarting earlier (Kitahata et al., 2009; Traynor, 2010). Addition-
lly, antiretroviral treatment with adequate adherence is known
o decrease the likelihood that an individual will transmit the HIV
irus (Quinn et al., 2003), leading to a movement to ‘Seek, Test and
reat’ (Hayden, 2010) as an HIV prevention strategy.
.3. Issues to address in future interventions
Overall low rates of engagement pointed to a need for pro-
edures to enhance engagement for this population. Results of
ubgroup analyses (Mitrani et al., in press) suggested that women
ivingwith children engaged at higher rates. Thus, targeting family-
cological interventions at women based on family context may
acilitate relapse prevention. Another issue related to engagement
as the high individual cost to family therapy. Involvement of fam-
ly members adds an additional burden of organization, as well as
he stress of families working through issues. It may be that even
or women who might beneﬁt from family involvement, a hybrid
pproach (family and non-family sessions) could lower these costs.
hybrid approach might also facilitate longer-run therapeutic
ollow-up as with Recovery Management Check-ups (Dennis et al.,
003; Scott et al., 2005).
The mixed drug use and medication adherence results indicate
need to addpotency to the SET intervention, possibly through fur-
her integrationwith drug treatment andHIV care. Integrationwith
rug treatment would allow the intervention to begin at the end
f drug treatment. The reality of recruitment for the current trial
ecessitated a mixed strategy of recruitment from drug treatment,
IV care, and from word-of-mouth and local outreach. Community
mplementation of the SETmodel as a hybrid aftercaremodel could
rovide a true bridge between treatment and maintenance from a
hronic disease perspective. Given the increase in drug use of the
omen within SET after the 4-month treatment period, a longer
nd ﬂexible tapering of drug treatment services may be warranted
s successfully implemented by Dennis et al. (2003).
Closer integration with HIV care would also be desirable to
mprove HIV medication adherence. Many of the women entering
he studynot takingHIVmedications reported that their doctor had
old them that they were healthy and did not need medications,
espite laboratory values indicating that HIV medications should
e seriously considered. This type of triangulation (between thera-
ist, woman, and physician) is one of the interaction patterns that
ETaims to change. Embedding theSET intervention in anHIVclinic
ight facilitate the transformation of this type of communication
attern between the woman, her family and health care. This inte-
ration could allow therapists to directly work with resistance to
rescribing HIV medications for women in recovery (Bogart et al.,
000; Wong et al., 2004). Integrating an aftercare intervention in
wo different systems—drug treatment and HIV care—is likely to
e challenging for clients and agency staff, but there is a growing
mpetus for integratedcare (Calsynet al., 2004;Mertenset al., 2008;
ylla et al., 2007).Please cite this article in press as: Feaster, D.J., et al., A randomized controlled
and substance abuse relapse prevention. Drug Alcohol Depend. (2010), doi
.4. Limitations
The results of this study need to be interpreted in the light of
everal limitations. First, the study had a relatively low rate of
ngagement into treatment. Second, the substance use outcomes PRESS
ependence xxx (2010) xxx–xxx 7
are self-reports. There was agreement between the urine drug
screens and self-report, but the 2-month interval between biolog-
ical assessments makes it difﬁcult to get a full picture based on
biologicalmeasures. Although self-reportsmay bias reports of drug
use downward, randomization to condition should balance this
across condition. Third, the sample was quite heterogeneous, with
a mixture of volunteers recruited from residential and outpatient
drug treatment and HIV treatment providers, and self-referrals
from word-of-mouth. Fourth, the study mixed women on HIV
antiretroviral medication at baseline and women not taking medi-
cations (though in the range of HIV infection that medications are
to be considered). The original reason for the inclusion of a mixed
study design of this nature was the ecological validity of an after-
careprogramthat couldbeused to targetmostHIV+womengetting
out of drug treatment. This mixed population dilutes the ability
to uncover a difference on particular components of adherence.
For example, SET increased the number of women on a medica-
tion regimen. Despite increasing ecological validity, the fraction of
the sample that started the study without medications decreases
power for test of treatment effects.
An additional limitation is the use of only self-report of HIV
medication adherence. As with the self-report of drug use, this is
unlikely to bias treatment comparisons; however, self-reports typ-
ically over-estimate actual medication adherence. The study used
a Medical Events Monitoring Systems (MEMS) Caps from AARDEX
group, medication bottle caps with a computer chip to measure
adherence. Unfortunately, use of the caps by the women was spo-
radic and caps were frequently lost. Even though replacement caps
were provided, the extreme amount of missing data precluded
analysis.
In conclusion, the SET intervention was not overwhelmingly
supported by this trial; however, SET established boundaries with
drug-using family and friends and facilitated engagement into drug
treatment in response to relapse. SET also was associated with an
increase in CD4-cell count, likely related to the increased medica-
tion initiation of women in SET. Despite this evidence of effects
of the intervention, engagement was unacceptably low and future
efforts need to explore a more targeted population and enhanced
engagement strategies. The lack of an empirically validated inter-
vention for women dually diagnosed with HIV and substance
abuse/dependence highlights the importance of continuing modi-
ﬁcations of SET to increase effectiveness.
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Appendix	  C:
Univariate	  Analysis	  for	  Repeated	  Measure	  HAART	  Adherence
1
Predictors Odds Ratio p
Education
Less than HS 0.315 0.007
HS diploma or GED 0.421 0.067
SSQ-Availability 1.323 0.036
Race/Ethnicity 0.516 0.122
Sexual Orientation 0.494 0.137
Language 0.341 0.139
SSQ-Satisfaction 0.748 0.199
Disclosure Concerns 0.968 0.228
Concerns about Public Attitude 0.988 0.334
Year of Diagnosis 1.028 0.336
Foreign born 0.604 0.355
Mean Significant Other Support 0.847 0.396
Mean Friend Support 1.103 0.402
Overall Stigma Score 0.994 0.413
Members in Support Network 1.050 0.421
Age 1.017 0.470
Have Children 0.724 0.518
On Public Assistance 1.237 0.582
Last CD4 count 1.000 0.607
Family income 1.000 0.618
Negative Self-Image 0.990 0.626
Marital Status
Never married and not living w/partner 0.450 0.106
Married and living together 0.577 0.422
Married but living apart 0.384 0.166
Living w/partner 0.564 0.322
Widowed 0.659 0.550
Personalized Stigma 0.996 0.744
Disclosure Proportion 0.957 0.938
Employment 1.041 0.939
Overall Support Score 1.010 0.951
Mean Family Support 0.992 0.952
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Appendix	  C:
Univariate	  Analysis	  for	  Repeated	  Measure	  Viral	  Load
1
Predictors Beta p
On HAART regimen 1.015 0.000
Baseline Adherence 0.578 0.001
Race/Ethnicity -0.553 0.085
Marital Status
Never married and not living w/partner -0.131 0.616
Married and living together 0.624 0.181
Married but living apart -0.395 0.293
Living w/partner 0.442 0.211
Widowed 0.149 0.743
Year of Diagnosis 0.021 0.230
Disclosure Proportion 0.330 0.386
On Public Assistance 0.234 0.399
Disclosure Concerns 0.013 0.440
Foreign born -0.235 0.508
SSQ-Satisfaction -0.109 0.521
Mean Family Support -0.056 0.524
Sexual Orientation -0.158 0.611
SSQ-Availability 0.044 0.612
Employment 0.149 0.652
Language -0.220 0.658
Family income 0.000 0.701
Age -0.005 0.702
Overall Stigma Score 0.002 0.739
Concerns about Public Attitude 0.002 0.767
Mean Friend Support 0.022 0.772
Have Children 0.081 0.775
Education
Less than HS -0.094 0.738
HS diploma or GED 0.074 0.816
Overall Support Score -0.021 0.849
Mean Significant Other Support 0.020 0.857
Personalized Stigma 0.002 0.864
Members in Support Network -0.005 0.897
Negative Self-Image 0.001 0.965
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Appendix	  C:
Univariate	  Analysis	  for	  Repeated	  Measure	  CD4	  Count
1
Predictors Beta p
On HAART regimen 0.168 0.002
Employment -0.199 0.004
Year of Diagnosis -0.010 0.055
Language -0.132 0.058
Race/Ethnicity -0.098 0.125
Foreign born -0.087 0.201
Marital Status 
Never married and not living w/partner 0.063 0.626
Married and living together 0.062 0.661
Married but living apart 0.251 0.080
Living w/partner -0.014 0.922
Widowed 0.016 0.923
Have Children 0.075 0.244
Mean Significant Other Support -0.029 0.258
Negative Self-Image -0.004 0.282
Concerns about Public Attitude -0.002 0.291
Family income 0.000 0.326
Personalized Stigma -0.002 0.338
Overall Stigma Score -0.001 0.377
Sexual Orientation -0.071 0.386
Age 0.005 0.388
Availability of Social Support -0.033 0.404
Mean Family Support -0.019 0.440
Overall Support Score -0.019 0.447
Size of Support Network 0.006 0.553
Education
Less than HS -0.051 0.459
HS diploma or GED -0.076 0.406
Disclosure Proportion 0.028 0.737
Satisfaction with Social Support -0.009 0.773
On Public Assistance -0.010 0.876
Disclosure Concerns -0.001 0.926
Baseline Adherence 0.005 0.934
Mean Friend Support 0.000 1.000
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Appendix D:  Multivariate Analysis for HAART Adherence
Model # Predictors Odds Ratio p
1 Randomization Assignment 0.919 0.766
Randomization Assignment 0.913 0.753
Time Elapsed 0.999 0.041
Randomization Assignment 0.820 0.581
Time Elapsed 0.998 0.078
Randomization Assignment x Time Elapsed 1.001 0.603
Randomization Assignment 0.890 0.748
Time Elapsed 0.998 0.097
Randomization Assignment x Time Elapsed 1.001 0.683
Education = 0 0.712 0.367
Education = 1 0.929 0.862
Randomization Assignment 0.830 0.602
Time Elapsed 0.998 0.087
Randomization Assignment x Time Elapsed 1.001 0.609
Social Support Availability 1.080 0.400
Randomization Assignment 0.811 0.557
Time Elapsed 0.998 0.077
Randomization Assignment x Time Elapsed 1.001 0.610
Race/Ethnicity 0.556 0.082
Randomization Assignment 0.818 0.575
Time Elapsed 0.998 0.058
Randomization Assignment x Time Elapsed 1.001 0.592
Race/Ethnicity 0.611 0.141
Social Support Satisfaction 0.792 0.071
Randomization Assignment 0.860 0.682
Time Elapsed 0.999 0.143
Randomization Assignment x Time Elapsed 1.000 0.826
Social Support Satisfaction 0.799 0.070
Year of Diagnosis 1.026 0.305
Randomization Assignment 0.809 0.555
Time Elapsed 0.998 0.057
Randomization Assignment x Time Elapsed 1.001 0.552
Social Support Satisfaction 0.779 0.046
Overall Stigma Score 1.001 0.819
Randomization Assignment 0.845 0.647
Time Elapsed 0.998 0.079
Randomization Assignment x Time Elapsed 1.000 0.744
Social Support Satisfaction 0.779 0.037
Size of Network 0.975 0.660
Randomization Assignment 0.884 0.736
Time Elapsed 0.998 0.060
Randomization Assignment x Time Elapsed 1.001 0.615
Social Support Satisfaction 0.777 0.044
Age 0.990 0.607
8
2
4
5
6
7
9
10
11
3
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Randomization Assignment 0.878 0.720
Time Elapsed 0.998 0.079
Randomization Assignment x Time Elapsed 1.001 0.670
Social Support Satisfaction 0.783 0.051
On Public Assistance 1.288 0.459
Randomization Assignment 0.933 0.862
Time Elapsed 0.999 0.155
Randomization Assignment x Time Elapsed 1.000 0.851
Social Support Satisfaction 0.781 0.050
Last CD4 Count 1.000 0.771
Randomization Assignment 0.799 0.564
Time Elapsed 0.998 0.109
Randomization Assignment x Time Elapsed 1.000 0.865
Social Support Satisfaction 0.830 0.147
Family Income 1.000 0.168
Randomization Assignment 0.845 0.638
Time Elapsed 0.998 0.065
Randomization Assignment x Time Elapsed 1.000 0.750
Social Support Satisfaction 0.775 0.036
Disclosure Proportion 1.906 0.181
Randomization Assignment 0.862 0.682
Time Elapsed 0.998 0.057
Randomization Assignment x Time Elapsed 1.001 0.608
Social Support Satisfaction 0.779 0.046
Employment 1.082 0.854
Randomization Assignment 0.789 0.513
Time Elapsed 0.998 0.056
Randomization Assignment x Time Elapsed 1.001 0.665
Social Support Satisfaction 0.781 0.073
Mean Overall Support 1.028 0.806
Randomization Assignment 0.818 0.581
Time Elapsed 0.998 0.037
Randomization Assignment x Time Elapsed 1.001 0.578
Social Support Satisfaction 0.757 0.032
Disclosure Proportion 0.033 0.070
Overall Stigma Score 0.969 0.047
Disclosure Proportion x Overall Stigma Score 1.045 0.028
Randomization Assignment 0.752 0.443
Time Elapsed 0.998 0.035
Randomization Assignment x Time Elapsed 1.001 0.612
Social Support Satisfaction 0.742 0.048
Disclosure Proportion 0.142 0.493
Overall Stigma Score 0.967 0.048
Disclosure Proportion x Overall Stigma Score 1.049 0.018
Mean Overall Support 1.372 0.328
12
13
14
15
16
17
18
19
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Disclosure Proportion x Mean Overall Support 0.703 0.417
Randomization Assignment 0.843 0.636
Time Elapsed 0.998 0.043
Randomization Assignment x Time Elapsed 1.001 0.594
Social Support Satisfaction 0.725 0.016
Disclosure Proportion 0.040 0.122
Overall Stigma Score 0.969 0.064
Disclosure Proportion x Overall Stigma Score 1.045 0.034
Social Support Availability 1.246 0.270
Disclosure Proportion x Social Support Availability 0.931 0.797
Randomization Assignment 0.817 0.579
Time Elapsed 0.998 0.036
Randomization Assignment x Time Elapsed 1.001 0.558
Social Support Satisfaction 0.636 0.376
Overall Stigma Score 0.967 0.061
Disclosure Proportion 0.008 0.303
Disclosure Proportion x Overall Stigma Score 1.047 0.037
Disclosure Proportion x Social Support Satisfaction 1.231 0.719
Randomization Assignment 0.814 0.580
Time Elapsed 0.998 0.039
Randomization Assignment x Time Elapsed 1.001 0.571
Social Support Satisfaction 0.758 0.032
Overall Stigma Score 0.967 0.037
Disclosure Proportion 0.007 0.023
Disclosure Proportion x Overall Stigma Score 1.047 0.022
Size of Network 0.797 0.246
Disclosure Proportion x Size of Network 1.288 0.250
Randomization Assignment 0.750 0.438
Time Elapsed 0.998 0.041
Randomization Assignment x Time Elapsed 1.001 0.658
Social Support Satisfaction 0.762 0.061
Disclosure Proportion 0.009 0.015
Overall Stigma Score 0.985 0.590
Disclosure Proportion x Overall Stigma Score 1.059 0.005
Mean Overall Support 1.573 0.292
Overall Stigma Score x Mean Overall Support 0.995 0.345
Randomization Assignment 0.846 0.642
Time Elapsed 0.998 0.043
Randomization Assignment x Time Elapsed 1.001 0.610
Social Support Satisfaction 0.717 0.016
Disclosure Proportion 0.034 0.081
Overall Stigma Score 0.967 0.070
Disclosure Proportion x Overall Stigma Score 1.045 0.033
Social Support Availability 1.059 0.852
Overall Stigma Score x Social Support Availability 1.001 0.720
20
21
22
23
24
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Randomization Assignment 0.819 0.583
Time Elapsed 0.998 0.043
Randomization Assignment x Time Elapsed 1.001 0.543
Social Support Satisfaction 1.623 0.365
Disclosure Proportion 0.028 0.061
Overall Stigma Score 1.008 0.793
Disclosure Proportion x Overall Stigma Score 1.048 0.021
Overall Stigma Score x Social Support Satisfaction 0.993 0.134
Randomization Assignment 0.839 0.634
Time Elapsed 0.998 0.041
Randomization Assignment x Time Elapsed 1.001 0.588
Social Support Satisfaction 0.762 0.032
Disclosure Proportion 0.058 0.147
Overall Stigma Score 0.987 0.551
Disclosure Proportion x Overall Stigma Score 1.039 0.069
Size of Network 1.278 0.172
Overall Stigma Score x Size of Network 0.997 0.146
Randomization Assignment 0.823 0.592
Time Elapsed 0.997 0.098
Randomization Assignment x Time Elapsed 1.001 0.584
Social Support Satisfaction 0.761 0.037
Disclosure Proportion 0.027 0.056
Overall Stigma Score 0.968 0.051
Disclosure Proportion x Overall Stigma Score 1.045 0.031
Time Elapsed x Disclosure Proposition 1.002 0.495
Randomization Assignment 0.825 0.599
Time Elapsed 0.996 0.170
Randomization Assignment x Time Elapsed 1.001 0.573
Social Support Satisfaction 0.752 0.032
Disclosure Proportion 0.032 0.063
Overall Stigma Score 0.966 0.041
Disclosure Proportion x Overall Stigma Score 1.045 0.023
Time Elapsed x Overall Stigma Score 1.000 0.557
Randomization Assignment 0.754 0.453
Time Elapsed 1.004 0.291
Randomization Assignment x Time Elapsed 1.001 0.509
Social Support Satisfaction 0.759 0.055
Disclosure Proportion 0.014 0.021
Overall Stigma Score 0.965 0.021
Disclosure Proportion x Overall Stigma Score 1.054 0.006
Mean Overall Support 1.270 0.153
Time Elapsed x Mean Overall Support 0.999 0.096
Randomization Assignment 0.777 0.502
Time Elapsed 1.004 0.259
Randomization Assignment x Time Elapsed 1.001 0.533
25
26
27
28
29
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Social Support Satisfaction 0.728 0.029
Disclosure Proportion 0.014 0.022
Overall Stigma Score 0.964 0.020
Disclosure Proportion x Overall Stigma Score 1.055 0.006
Mean Overall Support 1.181 0.326
Time Elapsed x Mean Overall Support 0.999 0.236
Social Support Availability 1.395 0.015
Time Elapsed x Social Support Availability 0.999 0.101
Randomization Assignment 0.839 0.632
Time Elapsed 0.998 0.590
Randomization Assignment x Time Elapsed 1.001 0.578
Social Support Satisfaction 0.664 0.026
Disclosure Proportion 0.027 0.059
Overall Stigma Score 0.966 0.036
Disclosure Proportion x Overall Stigma Score 1.048 0.019
Social Support Availability 1.451 0.006
Time Elapsed x Social Support Availability 0.999 0.046
Time Elapsed x Social Support Satisfaction 1.000 0.497
Randomization Assignment 0.825 0.606
Time Elapsed 1.000 0.854
Randomization Assignment x Time Elapsed 1.001 0.573
Social Support Satisfaction 0.731 0.015
Disclosure Proportion 0.026 0.055
Overall Stigma Score 0.967 0.037
Disclosure Proportion x Overall Stigma Score 1.047 0.019
Social Support Availability 1.455 0.006
Time Elapsed x Social Support Availability 0.999 0.048
Size of Network 0.957 0.468
Time Elapsed x Size of Network 1.000 0.521
Randomization Assignment 0.873 0.744
Time Elapsed 1.001 0.742
Randomization Assignment x Time Elapsed 1.000 0.753
Disclosure Proportion 0.013 0.029
Overall Stigma Score 0.962 0.022
Social Support Availability 1.495 0.002
Social Support Satisfaction 0.700 0.025
Disclosure Proportion x Overall Stigma Score 1.053 0.011
Time Elapsed x Social Support Availability 0.999 0.065
Last CD4 Count 0.996 0.075
Mean Overall Support 0.677 0.097
Last CD4 Count x Mean Overall Support 1.001 0.062
Randomization Assignment 0.850 0.701
Time Elapsed 1.001 0.773
Randomization Assignment x Time Elapsed 1.001 0.723
Disclosure Proportion 0.013 0.037
31
33
32
30
138
Appendix D:  Multivariate Analysis for HAART Adherence
Overall Stigma Score 0.962 0.031
Social Support Availability 1.706 0.008
Social Support Satisfaction 0.698 0.023
Disclosure Proportion x Overall Stigma Score 1.052 0.017
Time Elapsed x Social Support Availability 0.999 0.064
Last CD4 Count 0.996 0.103
Mean Overall Support 0.658 0.070
Last CD4 Count x Mean Overall Support 1.001 0.035
Last CD4 Count x Social Support Availability 1.000 0.312
Randomization Assignment 0.861 0.722
Time Elapsed 1.001 0.754
Randomization Assignment x Time Elapsed 1.001 0.729
Disclosure Proportion 0.013 0.029
Overall Stigma Score 0.962 0.021
Social Support Availability 1.492 0.003
Social Support Satisfaction 0.758 0.338
Disclosure Proportion x Overall Stigma Score 1.053 0.011
Time Elapsed x Social Support Availability 0.999 0.064
Last CD4 Count 0.997 0.356
Mean Overall Support 0.662 0.079
Last CD4 Count x Mean Overall Support 1.001 0.030
Last CD4 Count x Social Support Satisfaction 1.000 0.794
Randomization Assignment 0.865 0.730
Time Elapsed 1.001 0.739
Randomization Assignment x Time Elapsed 1.001 0.741
Disclosure Proportion 0.013 0.031
Overall Stigma Score 0.963 0.025
Social Support Availability 1.505 0.002
Social Support Satisfaction 0.694 0.027
Disclosure Proportion x Overall Stigma Score 1.052 0.014
Time Elapsed x Social Support Availability 0.999 0.065
Last CD4 Count 0.997 0.327
Mean Overall Support 0.691 0.122
Last CD4 Count x Mean Overall Support 1.001 0.088
Size of Network 1.085 0.469
Last CD4 Count x Size of Network 1.000 0.277
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Model # Predictors Beta p
1 Randomization Assignment -0.036 0.848
Randomization Assignment -0.036 0.853
Time Elapsed 0.000 0.546
Randomization Assignment 0.072 0.758
Time Elapsed 4.137E-05 0.940
Randomization Assignment x Time Elapsed -0.001 0.403
Randomization Assignment -0.003 0.990
Time Elapsed 0.000 0.685
Randomization Assignment x Time Elapsed 0.000 0.556
On HAART Regimen -1.068 0.000
Randomization Assignment 0.015 0.943
Time Elapsed 0.000 0.639
Randomization Assignment x Time Elapsed 0.000 0.529
On HAART Regimen -1.076 0.000
Baseline Adherence -0.094 0.646
Randomization Assignment -0.001 0.998
Time Elapsed 0.000 0.658
Randomization Assignment x Time Elapsed 0.000 0.536
On HAART Regimen -1.116 0.000
Race/Ethnicity 0.276 0.204
Randomization Assignment -0.029 0.895
Time Elapsed 5.370E-05 0.918
Randomization Assignment x Time Elapsed 0.000 0.723
On HAART Regimen -1.111 0.000
Year of Diagnosis -0.008 0.595
Randomization Assignment -4.497E-05 1.000
Time Elapsed 0.000 0.841
Randomization Assignment x Time Elapsed 0.000 0.557
On HAART Regimen -1.103 0.000
Disclosure Proportion 0.621 0.010
Randomization Assignment -0.031 0.883
Time Elapsed 3.256E-05 0.953
Randomization Assignment x Time Elapsed 0.000 0.648
On HAART Regimen 1.136 0.000
Disclosure Proportion 0.605 0.012
On Public Assistance 0.175 0.415
Randomization Assignment 0.023 0.914
Time Elapsed 0.000 0.729
Randomization Assignment x Time Elapsed 0.000 0.517
On HAART Regimen -1.051 0.000
Disclosure Proportion 0.598 0.013
Satisfaction with Social Support 0.006 0.918
Randomization Assignment 0.011 0.958
Time Elapsed 0.000 0.794
9
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Randomization Assignment x Time Elapsed 0.000 0.538
On HAART Regimen -1.085 0.000
Disclosure Proportion 0.626 0.010
Availability of Support 0.065 0.179
Randomization Assignment -0.018 0.934
Time Elapsed 0.000 0.831
Randomization Assignment x Time Elapsed 0.000 0.540
On HAART Regimen -1.117 0.000
Disclosure Proportion 0.596 0.014
Employment Status -0.143 0.569
Randomization Assignment -0.139 0.550
Time Elapsed 0.000 0.426
Randomization Assignment x Time Elapsed 0.000 0.725
On HAART Regimen -1.087 0.000
Disclosure Proportion 0.647 0.007
Family Income -7.794E-06 0.567
Randomization Assignment -0.009 0.967
Time Elapsed 0.000 0.832
Randomization Assignment x Time Elapsed 0.000 0.562
On HAART Regimen -1.106 0.000
Disclosure Proportion 0.617 0.011
Age -0.011 0.329
Randomization Assignment -0.017 0.936
Time Elapsed 7.711E-05 0.886
Randomization Assignment x Time Elapsed 0.000 0.593
On HAART Regimen -1.100 0.000
Disclosure Proportion 0.653 0.005
Overall Stigma Score 0.005 0.076
Randomization Assignment -0.300 0.886
Time Elapsed 7.235E-05 0.894
Randomization Assignment x Time Elapsed 0.000 0.601
On HAART Regimen -1.140 0.000
Disclosure Proportion 0.627 0.007
Overall Stigma Score 0.005 0.071
Education = 0 0.289 0.181
Education = 1 0.342 0.176
Randomization Assignment -0.008 0.969
Time Elapsed 9.932E-05 0.859
Randomization Assignment x Time Elapsed 0.000 0.553
On HAART Regimen -1.132 0.000
Disclosure Proportion 0.687 0.004
Overall Stigma Score 0.004 0.151
Mean Overall Support -0.072 0.243
Randomization Assignment 0.034 0.874
Time Elapsed -2.596E-05 0.960
11
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Randomization Assignment x Time Elapsed 0.000 0.546
On HAART Regimen -1.086 0.000
Disclosure Proportion 0.879 0.000
Overall Stigma Score 0.005 0.057
Size of Network 0.076 0.004
Randomization Assignment 0.034 0.872
Time Elapsed -1.115E-05 0.983
Randomization Assignment x Time Elapsed 0.000 0.525
On HAART Regimen -1.095 0.000
Disclosure Proportion 1.263 0.244
Overall Stigma Score 0.008 0.404
Size of Network 0.076 0.004
Disclosure Proportion x Overall Stigma Score -0.004 0.730
Randomization Assignment 0.050 0.818
Time Elapsed 2.368E-05 0.965
Randomization Assignment x Time Elapsed 0.000 0.495
On HAART Regimen -1.118 0.000
Disclosure Proportion -0.141 0.910
Overall Stigma Score 0.004 0.147
Size of Network 0.077 0.004
Mean Overall Support -0.212 0.178
Disclosure Proportion x Mean Overall Support 0.195 0.376
Randomization Assignment 0.040 0.853
Time Elapsed 4.549E-06 0.993
Randomization Assignment x Time Elapsed 0.000 0.536
On HAART Regimen -1.068 0.000
Disclosure Proportion 0.814 0.054
Overall Stigma Score 0.006 0.039
Size of Network 0.071 0.008
Social Support Availability 0.038 0.817
Disclosure Proportion x Social Support Availability 0.032 0.873
Randomization Assignment 0.056 0.792
Time Elapsed 5.095E-05 0.922
Randomization Assignment x Time Elapsed -0.001 0.482
On HAART Regimen -1.037 0.000
Disclosure Proportion 1.811 0.257
Overall Stigma Score 0.005 0.077
Size of Network 0.076 0.004
Social Support Satisfaction 0.155 0.491
Disclosure Proportion x Social Support Satistfaction -0.166 0.543
Randomization Assignment 0.034 0.872
Time Elapsed -2.603E-05 0.960
Randomization Assignment x Time Elapsed 0.000 0.546
On HAART Regimen -1.082 0.000
Disclosure Proportion 0.582 0.358
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Overall Stigma Score 0.005 0.056
Size of Network 0.032 0.711
Disclosure Proportion x Size of Network 0.052 0.596
Randomization Assignment 0.044 0.839
Time Elapsed 3.479E-05 0.949
Randomization Assignment x Time Elapsed -0.001 0.461
On HAART Regimen -1.116 0.000
Disclosure Proportion 0.927 0.000
Overall Stigma Score 0.015 0.198
Size of Network 0.076 0.005
Mean Overall Support 0.097 0.625
Overall Stigma Score x Mean Overall Support -0.002 0.356
Randomization Assignment 0.039 0.856
Time Elapsed 3.292E-06 0.995
Randomization Assignment x Time Elapsed 0.000 0.547
On HAART Regimen -1.065 0.000
Disclosure Proportion 0.875 0.001
Overall Stigma Score 0.007 0.145
Size of Network 0.071 0.008
Social Support Availability 0.115 0.537
Overall Stigma Score x Social Support Availability -0.001 0.770
Randomization Assignment 0.056 0.795
Time Elapsed 4.907E-05 0.925
Randomization Assignment x Time Elapsed 0.000 0.512
On HAART Regimen -1.041 0.000
Disclosure Proportion 0.853 0.001
Overall Stigma Score 0.004 0.733
Size of Network 0.076 0.004
Social Support Satisfaction -0.005 0.981
Overall Stigma Score x Social Support Satisfaction 0.000 0.921
Randomization Assignment 0.053 0.806
Time Elapsed -2.692E-05 0.958
Randomization Assignment x Time Elapsed 0.000 0.551
On HAART Regimen -1.077 0.000
Disclosure Proportion 0.875 0.000
Overall Stigma Score 0.012 0.041
Size of Network 0.204 0.017
Overall Stigma Score x Size of Network -0.001 0.127
Randomization Assignment 0.024 0.911
Time Elapsed 0.002 0.201
Randomization Assignment x Time Elapsed 0.000 0.538
On HAART Regimen -1.101 0.000
Disclosure Proportion 1.213 0.001
Overall Stigma Score 0.005 0.046
Size of Network 0.074 0.006
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Time Elapsed x Disclosure Proportion -0.002 0.151
Randomization Assignment 0.037 0.863
Time Elapsed -0.001 0.660
Randomization Assignment x Time Elapsed 0.000 0.547
On HAART Regimen -1.091 0.000
Disclosure Proportion 0.873 0.000
Overall Stigma Score 0.004 0.421
Size of Network 0.076 0.004
Time Elapsed x Overall Stigma Score 8.221E-06 0.651
Randomization Assignment 0.044 0.837
Time Elapsed -0.001 0.677
Randomization Assignment x Time Elapsed -0.001 0.478
On HAART Regimen -1.123 0.000
Disclosure Proportion 0.909 0.000
Overall Stigma Score 0.004 0.137
Size of Network 0.075 0.005
Mean Overall Support -0.094 0.280
Time Elapsed x Mean Overall Support 0.000 0.647
Randomization Assignment 0.035 0.869
Time Elapsed 0.000 0.524
Randomization Assignment x Time Elapsed 0.000 0.534
On HAART Regimen -1.071 0.000
Disclosure Proportion 0.859 0.001
Overall Stigma Score 0.006 0.038
Size of Network 0.071 0.008
Social Support Availability 0.019 0.744
Time Elapsed x Social Support Availability 0.000 0.303
Randomization Assignment 0.056 0.792
Time Elapsed 0.000 0.872
Randomization Assignment x Time Elapsed 0.000 0.509
On HAART Regimen -1.041 0.000
Disclosure Proportion 0.852 0.001
Overall Stigma Score 0.005 0.080
Size of Network 0.076 0.004
Social Support Satisfaction 0.026 0.832
Time Elapsed x Social Support Satisfaction -4.704E-05 0.891
Randomization Assignment 0.018 0.930
Time Elapsed -0.001 0.164
Randomization Assignment x Time Elapsed 0.000 0.546
On HAART Regimen -1.072 0.000
Disclosure Proportion 0.854 0.001
Overall Stigma Score 0.005 0.058
Size of Network 0.040 0.221
Time Elapsed x Size of Network 0.000 0.088
Randomization Assignment 0.036 0.867
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Time Elapsed -0.001 0.188
Randomization Assignment x Time Elapsed -0.001 0.472
On HAART Regimen -1.107 0.000
Disclosure Proportion 0.864 0.001
Overall Stigma Score 0.005 0.114
Size of Network 0.038 0.243
Time Elapsed x Size of Network 0.000 0.085
Baseline Adherence 0.243 0.734
Mean Overall Support -0.024 0.794
Baseline Adherence x Mean Overall Support -0.055 0.657
Randomization Assignment 0.041 0.846
Time Elapsed -0.001 0.238
Randomization Assignment x Time Elapsed 0.000 0.546
On HAART Regimen -1.068 0.000
Disclosure Proportion 0.768 0.002
Overall Stigma Score 0.006 0.035
Size of Network 0.031 0.349
Time Elapsed x Size of Network 0.000 0.097
Baseline Adherence 0.204 0.442
Social Support Availability 0.141 0.029
Baseline Adherence x Social Support Availability -0.155 0.105
Randomization Assignment 0.067 0.751
Time Elapsed -0.001 0.265
Randomization Assignment x Time Elapsed -0.001 0.457
On HAART Regimen -1.026 0.000
Disclosure Proportion 0.800 0.001
Overall Stigma Score 0.005 0.110
Size of Network 0.044 0.175
Time Elapsed x Size of Network 0.000 0.114
Baseline Adherence -0.758 0.296
Social Support Satisfaction -0.037 0.658
Baseline Adherence x Social Support Satisfaction 0.116 0.330
Randomization Assignment 0.031 0.884
Time Elapsed -0.001 0.201
Randomization Assignment x Time Elapsed 0.000 0.511
On HAART Regimen -1.088 0.000
Disclosure Proportion 0.816 0.002
Overall Stigma Score 0.005 0.066
Size of Network 0.048 0.189
Time Elapsed x Size of Network 0.000 0.100
Baseline Adherence 0.002 0.996
Baseline Adherence x Size of Network -0.015 0.780
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Model # Predictors Beta p
1 Randomization Assignment 0.004 0.946
Randomization Assignment 0.000 0.995
Time Elapsed -9.552E-05 0.258
Randomization Assignment -0.056 0.390
Time Elapsed 0.000 0.009
Randomization Assignment x Time Elapsed 0.000 0.045
Randomization Assignment -0.048 0.472
Time Elapsed 0.000 0.004
Randomization Assignment x Time Elapsed 0.000 0.055
On HAART Regimen 0.113 0.015
Randomization Assignment -0.039 0.558
Time Elapsed 0.000 0.004
Randomization Assignment x Time Elapsed 0.000 0.039
On HAART Regimen 0.112 0.017
Employment Status -0.108 0.203
Randomization Assignment -0.048 0.480
Time Elapsed 0.000 0.020
Randomization Assignment x Time Elapsed 0.000 0.075
On HAART Regimen 0.120 0.012
Year of Diagnosis 0.004 0.430
Randomization Assignment -0.060 0.376
Time Elapsed 0.000 0.004
Randomization Assignment x Time Elapsed 0.000 0.037
On HAART Regimen 0.115 0.015
Race/Ethnicity -0.102 0.166
Randomization Assignment -0.042 0.587
Time Elapsed 0.000 0.033
Randomization Assignment x Time Elapsed 0.000 0.153
On HAART Regimen 0.121 0.023
Family Income 4.550E-06 0.300
Randomization Assignment -0.040 0.547
Time Elapsed 0.000 0.003
Randomization Assignment x Time Elapsed 0.000 0.067
On HAART Regimen 0.114 0.014
Overall Stigma Score -0.001 0.291
Randomization Assignment -0.046 0.510
Time Elapsed 0.000 0.004
Randomization Assignment x Time Elapsed 0.000 0.038
On HAART Regimen 0.112 0.017
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Age -0.001 0.881
Randomization Assignment -0.050 0.444
Time Elapsed 0.000 0.002
Randomization Assignment x Time Elapsed 0.000 0.048
On HAART Regimen 0.107 0.015
Social Support Availability -0.021 0.028
Randomization Assignment -0.052 0.437
Time Elapsed 0.000 0.003
Randomization Assignment x Time Elapsed 0.000 0.076
On HAART Regimen 0.110 0.014
Social Support Availability -0.026 0.017
Mean Overall Support 0.005 0.671
Randomization Assignment -0.049 0.469
Time Elapsed 0.000 0.003
Randomization Assignment x Time Elapsed 0.000 0.072
On HAART Regimen 0.118 0.015
Social Support Availability -0.020 0.052
Size of Network -0.006 0.390
Randomization Assignment -0.050 0.456
Time Elapsed 0.000 0.002
Randomization Assignment x Time Elapsed 0.000 0.032
On HAART Regimen 0.106 0.017
Social Support Availability -0.022 0.021
Education=0 -0.075 0.205
Education=1 -0.078 0.407
Randomization Assignment -0.043 0.518
Time Elapsed 0.000 0.003
Randomization Assignment x Time Elapsed 0.000 0.073
On HAART Regimen 0.117 0.017
Social Support Availability -0.020 0.045
Disclosure Proportion -0.049 0.353
Randomization Assignment -0.053 0.421
Time Elapsed 0.000 0.002
Randomization Assignment x Time Elapsed 0.000 0.044
On HAART Regimen 0.099 0.027
Social Support Availability -0.024 0.015
Social Support Satisfaction 0.010 0.282
Randomization Assignment -0.049 0.465
Time Elapsed 0.000 0.004
Randomization Assignment x Time Elapsed 0.000 0.040
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On HAART Regimen 0.110 0.015
Social Support Availability -0.022 0.023
On Public Assistance -0.057 0.398
Randomization Assignment -0.036 0.588
Time Elapsed 0.000 0.002
Randomization Assignment x Time Elapsed 0.000 0.076
On HAART Regimen 0.120 0.014
Social Support Availability -0.021 0.038
Overall Stigma Score -0.002 0.319
Disclosure Proportion -0.132 0.526
Disclosure Proportion x Overall Stigma Score 0.001 0.671
Randomization Assignment -0.044 0.507
Time Elapsed 0.000 0.004
Randomization Assignment x Time Elapsed 0.000 0.089
On HAART Regimen 0.121 0.017
Social Support Availability -0.024 0.035
Disclosure Proportion 0.024 0.886
Mean Overall Support 0.012 0.599
Disclosure Proportion x Mean Overall Support -0.013 0.647
Randomization Assignment -0.042 0.523
Time Elapsed 0.000 0.003
Randomization Assignment x Time Elapsed 0.000 0.075
On HAART Regimen 0.117 0.016
Social Support Availability -0.009 0.618
Disclosure Proportion -0.022 0.798
Disclosure Proportion x Social Support Availability -0.015 0.621
Randomization Assignment -0.045 0.492
Time Elapsed 0.000 0.002
Randomization Assignment x Time Elapsed 0.000 0.072
On HAART Regimen 0.111 0.027
Social Support Availability -0.022 0.030
Disclosure Proportion 0.157 0.577
Social Support Satisfaction 0.033 0.453
Disclosure Proportion x Social Support Satisfaction -0.034 0.478
Randomization Assignment -0.048 0.481
Time Elapsed 0.000 0.005
Randomization Assignment x Time Elapsed 0.000 0.072
On HAART Regimen 0.118 0.016
Social Support Availability -0.020 0.053
Disclosure Proportion -0.118 0.321
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Size of Network -0.015 0.349
Disclosure Proportion x Size of Network 0.009 0.656
Randomization Assignment -0.045 0.505
Time Elapsed 0.000 0.002
Randomization Assignment x Time Elapsed 0.000 0.074
On HAART Regimen 0.110 0.014
Social Support Availability -0.028 0.012
Overall Stigma Score -0.002 0.231
Mean Overall Support -0.020 0.512
Overall Stigma Score x Mean Overall Support 0.000 0.423
Randomization Assignment -0.043 0.521
Time Elapsed 0.000 0.002
Randomization Assignment x Time Elapsed 0.000 0.062
On HAART Regimen 0.108 0.015
Social Support Availability -0.032 0.310
Overall Stigma Score -0.001 0.290
Overall Stigma Score x Social Support Availability 0.000 0.757
Randomization Assignment -0.046 0.491
Time Elapsed 0.000 0.002
Randomization Assignment x Time Elapsed 0.000 0.055
On HAART Regimen 0.101 0.026
Social Support Availability -0.024 0.014
Overall Stigma Score -0.001 0.439
Social Support Satisfaction -0.003 0.914
Overall Stigma Score x Social Support Satisfaction 9.845E-05 0.737
Randomization Assignment -0.050 0.459
Time Elapsed 0.000 0.002
Randomization Assignment x Time Elapsed 0.000 0.083
On HAART Regimen 0.118 0.014
Social Support Availability -0.020 0.051
Overall Stigma Score -0.004 0.015
Size of Network -0.061 0.015
Overall Stigma Score x Size of Network 0.001 0.025
Randomization Assignment -0.052 0.448
Time Elapsed 0.000 0.465
Randomization Assignment x Time Elapsed 0.000 0.086
On HAART Regimen 0.114 0.016
Social Support Availability -0.018 0.074
Overall Stigma Score -0.004 0.015
Size of Network -0.066 0.008
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Overall Stigma Score x Size of Network 0.001 0.019
Disclosure of Proportion -0.030 0.605
Time Elapsed x Disclosure Proportion 0.000 0.048
Randomization Assignment -0.051 0.454
Time Elapsed 2.809E-05 0.934
Randomization Assignment x Time Elapsed 0.000 0.085
On HAART Regimen 0.113 0.015
Social Support Availability -0.018 0.075
Overall Stigma Score -0.004 0.010
Size of Network -0.064 0.013
Overall Stigma Score x Size of Network 0.001 0.028
Disclosure of Proportion -0.034 0.551
Time Elapsed x Disclosure Proportion 0.000 0.053
Time Elapsed x Overall Stigma Score 1.049E-06 0.721
Randomization Assignment -0.055 0.434
Time Elapsed 0.001 0.089
Randomization Assignment x Time Elapsed 0.000 0.089
On HAART Regimen 0.121 0.014
Social Support Availability -0.021 0.066
Overall Stigma Score -0.004 0.031
Size of Network -0.075 0.052
Overall Stigma Score x Size of Network 0.001 0.073
Disclosure of Proportion -0.050 0.410
Time Elapsed x Disclosure Proportion 0.000 0.108
Mean Overall Support 0.014 0.307
Time Elapsed x Mean Overall Support -8.014E-05 0.105
Randomization Assignment -0.050 0.465
Time Elapsed 0.000 0.295
Randomization Assignment x Time Elapsed 0.000 0.073
On HAART Regimen 0.113 0.010
Social Support Availability -0.001 0.928
Overall Stigma Score -0.004 0.015
Size of Network -0.065 0.008
Overall Stigma Score x Size of Network 0.001 0.021
Disclosure of Proportion -0.022 0.742
Time Elapsed x Disclosure Proportion 0.000 0.051
Time Elapsed x Social Support Availability 0.000 0.307
Randomization Assignment -0.054 0.433
Time Elapsed 0.001 0.201
Randomization Assignment x Time Elapsed 0.000 0.083
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On HAART Regimen 0.106 0.030
Social Support Availability -0.019 0.059
Overall Stigma Score -0.004 0.022
Size of Network -0.064 0.012
Overall Stigma Score x Size of Network 0.001 0.027
Disclosure of Proportion -0.029 0.622
Time Elapsed x Disclosure Proportion 0.000 0.041
Social Support Satisfaction 0.014 0.469
Time Elapsed x Social Support Satisfaction -6.566E-05 0.315
Randomization Assignment -0.050 0.463
Time Elapsed 0.000 0.227
Randomization Assignment x Time Elapsed 0.000 0.083
On HAART Regimen 0.112 0.018
Social Support Availability -0.018 0.075
Overall Stigma Score -0.004 0.014
Size of Network -0.063 0.022
Overall Stigma Score x Size of Network 0.001 0.015
Disclosure of Proportion -0.020 0.733
Time Elapsed x Disclosure Proportion 0.000 0.020
Time Elapsed x Size of Network -2.039E-05 0.474
Randomization Assignment -0.058 0.412
Time Elapsed 0.000 0.495
Randomization Assignment x Time Elapsed 0.000 0.099
On HAART Regimen 0.113 0.043
Social Support Availability -0.021 0.071
Overall Stigma Score -0.004 0.031
Size of Network -0.078 0.045
Overall Stigma Score x Size of Network 0.001 0.067
Disclosure of Proportion -0.027 0.646
Time Elapsed x Disclosure Proportion 0.000 0.049
Baseline Adherence -0.012 0.932
Mean Overall Support -0.002 0.912
Baseline Adherence x  Mean Overall Support 0.001 0.969
Randomization Assignment -0.051 0.459
Time Elapsed 0.000 0.487
Randomization Assignment x Time Elapsed 0.000 0.072
On HAART Regimen 0.117 0.025
Social Support Availability -0.007 0.558
Overall Stigma Score -0.004 0.017
Size of Network -0.066 0.008
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Overall Stigma Score x Size of Network 0.001 0.021
Disclosure of Proportion -0.034 0.561
Time Elapsed x Disclosure Proportion 0.000 0.053
Baseline Adherence 0.031 0.703
Baseline Adherence x  Social Support Availability -0.021 0.268
Randomization Assignment -0.055 0.421
Time Elapsed 0.000 0.489
Randomization Assignment x Time Elapsed 0.000 0.073
On HAART Regimen 0.109 0.046
Social Support Availability -0.019 0.053
Overall Stigma Score -0.004 0.034
Size of Network -0.062 0.015
Overall Stigma Score x Size of Network 0.001 0.033
Disclosure of Proportion -0.024 0.674
Time Elapsed x Disclosure Proportion 0.000 0.044
Baseline Adherence 0.136 0.336
Social Support Satisfaction 0.011 0.409
Baseline Adherence x  Social Support Satisfaction -0.024 0.159
Randomization Assignment -0.042 0.533
Time Elapsed 0.000 0.504
Randomization Assignment x Time Elapsed 0.000 0.073
On HAART Regimen 0.122 0.022
Social Support Availability -0.017 0.082
Overall Stigma Score -0.004 0.013
Size of Network -0.075 0.005
Overall Stigma Score x Size of Network 0.001 0.017
Disclosure of Proportion -0.041 0.488
Time Elapsed x Disclosure Proportion 0.000 0.046
Baseline Adherence -0.114 0.311
Baseline Adherence x  Size of Network 0.021 0.160
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